SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
COLLAGENEX PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 52-1758016
- --------------------------------------------------------------------------------
(State of incorporation or organization) (IRS Employer Identification No.)
301 South State Street
Newtown, Pennsylvania 18940
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
If this form relates to the registration of a class of securities pursuant to
Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), please check the following box. [ ]
If this form relates to the registration of a class of securities pursuant to
Section 12(g) of the Exchange Act and is effective pursuant to General
Instruction A.(d), please check the following box. [X]
Securities Act registration statement file number to which this form
relates:
------------------------------------------------------------
(if applicable)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be Name of each exchange on which each
so registered class is to be registered
None
(Title of Class)
Securities to be registered pursuant to Section 12(g) of the Act:
Preferred Stock Purchase Rights
(Title of Class)
<PAGE>
Item 1. Description of Registrant's Securities to be Registered.
The Board of Directors of CollaGenex Pharmaceuticals, Inc. (the
"Company") has declared a distribution of one preferred stock purchase right (a
"Right") for each outstanding common share, par value $0.01 per share (the
"Common Stock"), of the Company. The distribution is payable at the close of
business on September 26, 1997 to shareholders of record on September 26, 1997
(the "Record Date"). A Right will automatically attach to shares of the
Company's Common Stock issued after the Record Date. The description and terms
of the Rights are set forth in a Shareholder Protection Rights Agreement (the
"Rights Agreement") between the Company and American Stock Transfer & Trust
Company, as rights agent (the "Rights Agent"). Terms not otherwise defined
herein shall have the meanings set forth in the Rights Agreement which is
attached hereto and incorporated herein by reference.
The Rights Agreement provides for the issuance of one Right to buy one
one-hundredth (1/100) of a share of Series A Participating Preferred Stock, no
par value, to stockholders of the Common Stock as of the Record Date and to
stockholders of Common Stock issued thereafter. The Series A Participating
Preferred Stock is a series of the Company's authorized preferred stock (each
share, a "Preferred Share"), and is more fully described below.
The Rights will remain attached to and trade with the Common Stock until
the earlier to occur of (i) ten (10) business days following a public
announcement that a person or group of affiliated or associated persons (an
"Acquiring Person") has acquired, or obtained the right to acquire, beneficial
ownership of shares of the Company's Common Stock representing twenty percent
(20%) or more of the voting power of all outstanding shares of Common Stock of
the Company (the date of such announcement being referred to as the "Stock
Acquisition Date") or such later date as the Board of Directors of the Company
may determine by resolution adopted prior to the Separation Date (as defined
below), or (ii) ten (10) business days following the commencement of a tender
offer or exchange offer that would result in a person or group beneficially
owning outstanding shares of the Company's Common Stock representing twenty
percent (20%) or more of the voting power of all outstanding shares of Common
Stock of the Company, or such later date as the Board of Directors of the
Company may determine by resolution adopted prior to the Separation Date. The
earlier of (i) and (ii) is referred to as the "Separation Date." Following the
Separation Date, the Rights will detach from the Common Stock and will be
tradable separately from the Common Stock and Rights holders will be entitled to
purchase one one-hundredth (1/100) of a share of the Series A Participating
Preferred Stock for $65.
In the event that a person or group of affiliated or associated persons
becomes an Acquiring Person, on the Separation Date, each Right, other than
Rights held by the Acquiring Person, shall become exercisable for that number of
shares of Common Stock as shall have a market value equal to two times the then
applicable exercise price of the Right (or, at the option of the Company, shares
of Preferred Stock at a ratio of one one-hundredth (1/100) of a share of
-2-
<PAGE>
Preferred Stock for each share of Common Stock required to be issued). If the
Company shall not have sufficient treasury shares or authorized but unissued
shares of Common Stock or Preferred Stock to permit the full exercise of the
Rights, the Company may issue a combination of stock, cash and debt in respect
thereof. Following the time at which a person shall become an Acquiring Person
but prior to the acquisition by such Acquiring Person of more than 50% of the
Common Stock, the Board may also, at its option, exchange all of the then
outstanding rights (other than Rights held by the Acquiring Person) for shares
of Common Stock (or, at the option of the Board, Preferred Stock) at an exchange
ratio of one share of Common Stock (or one one-hundredth (1/100) of a share of
Preferred Stock) for each Right.
In the event that the Company is acquired in a merger or other business
combination transaction or 50% or more of its consolidated assets or earning
power are sold to an Acquiring Person, its associates or affiliates or certain
other persons in which such persons have an interest, each holder of a Right
will thereafter have the right to receive, upon the exercise thereof at the then
current exercise price of any Right, that number of shares of common stock of
the acquiring company which at the time of such transaction have a market value
equal to two times the exercise price of the Right.
Until the Separation Date, the Rights will be evidenced, with respect to
any of the Common Stock certificates outstanding as of the Record Date, by such
Common Stock certificate with a copy of the summary of Rights attached thereto.
Until the Separation Date (or earlier redemption or expiration of the Rights)
the Rights will be transferred with the Common Stock, and transfer of those
certificates will also constitute transfer of those Rights.
As soon as practicable following the Separation Date, separate
certificates evidencing the Rights ("Right Certificates") will be mailed to
holders of record of the Common Stock as of the close of business on the
Separation Date and such separate Right Certificates alone will thereafter
evidence the Rights.
The Rights are not exercisable until the Separation Date. The Rights will
expire on September 26, 2007 (the "Expiration Date"), unless the Expiration Date
is extended or unless the Rights are earlier redeemed or exchanged by the
Company, as described below.
The Exercise Price payable, and the number of shares of Preferred Stock or
other securities or property issuable, upon exercise of the Rights are subject
to adjustment from time to time to prevent dilution (i) in the event of a stock
dividend on, or a subdivision, combination or reclassification of, the Preferred
Stock, (ii) if holders of the Preferred Stock are granted certain rights or
warrants to subscribe for Preferred Stock or convertible securities at less than
the current market price of the Preferred Stock, or (iii) upon the distribution
to holders of the Preferred Stock of evidences of indebtedness or assets
(excluding regular quarterly cash dividends) or of subscription rights or
warrants. With certain exceptions, no adjustment in the
-3-
<PAGE>
Exercise Price will be required until cumulative adjustments amount to at least
one percent of the Exercise Price.
The number of outstanding Rights and the number of one one-hundredths of a
share of Preferred Stock issuable upon exercise of each Right are also subject
to adjustment in the event of a stock split of the Common Stock or a stock
dividend on the Common Stock payable in Common Stock or subdivisions,
consolidation or combinations of the Common Stock occurring, in any case, prior
to the Separation Date.
Preferred Shares purchasable upon exercise of the Rights will not be
redeemable. Each Preferred Share will be entitled to a minimum preferential
quarterly dividend payment equal to 25% of the Exercise Price of a Right as of
the Separation Date but will be entitled to an aggregate dividend of 100 times
any dividend declared per Common Share. In the event of liquidation, the holders
of the Preferred Shares would be entitled to a minimum preferential liquidation
payment equal to 100 times the Exercise Price of a Right as of the Separation
Date or an aggregate payment equal to 100 times the payment made per Common
Share. Each Preferred Share will have 100 votes, voting together with the Common
Shares. Finally, in the event of any merger, consolidation or other transaction
in which Common Shares are exchanged, each Preferred Share will be entitled to
receive 100 times the amount of consideration received per Common Share. These
rights are protected by customary anti-dilution provisions. Because of the
nature of the dividend and liquidation rights of the Preferred Shares, the value
of one one-hundredth of a Preferred Share should approximate the value of one
Common Share.
The Rights are redeemable at any time prior to ten (10) days after the
public announcement of an acquisition of beneficial ownership, by one party or
several parties acting as a group, of Common Stock representing at least twenty
percent (20%) voting power of the Company. In certain circumstances, redemption
will require the concurrence of a majority of the "Disinterested Directors." The
term "Disinterested Directors" means any member of the Board of Directors of the
Company who was a member of the Board prior to the time that the Acquiring
Person became an Acquiring Person, any person who is subsequently elected to the
Board to fill a vacancy created by an increase in the size of the Board if such
person is recommended or approved by a majority of the Disinterested Directors,
and any successor of a Disinterested Director if such person is recommended or
approved by a majority of the Disinterested Directors, but shall not include an
Acquiring Person, or an affiliate or associate of an Acquiring Person, or any
representative of the foregoing entities.
The terms of the Rights may be amended by the Board without the consent of
the holders of the Rights, except that after the Separation Date, no such
amendment may adversely affect the interest of the holders of the Rights (other
than the interests of the Acquiring Person).
Until a Right is exercised, the holder thereof, as such, will have no
rights as a stockholder of the Company, including, without limitation, the right
to vote or to receive dividends.
-4-
<PAGE>
The Rights have certain anti-takeover effects. The Rights would cause
substantial dilution to a person or group that attempts to acquire the Company
on terms not approved by the Company's Board, except pursuant to an offer
conditioned on a substantial number of Rights being acquired. The Rights should
not interfere with any merger or other business combination approved by the
Board since the Rights may be redeemed by the Company at the Redemption Price in
accordance with the provisions of the Rights Agreement.
The Shareholder Protection Rights Agreement between the Company and Rights
Agent, dated as of September 15, 1997, specifying the terms of the Rights and
including (i) the form of the Certificate of Designation as adopted by the
Directors of the Company, (ii) the form of Rights Certificate and (iii) the form
of Stockholder Letter announcing the declaration of the Rights are attached
hereto as exhibits and are incorporated herein by reference. The foregoing
description of the Rights is qualified in its entirety by reference to such
exhibits.
Item 2. Exhibits
--------
4.1 Shareholder Protection Rights Agreement, dated as of September 15,
1997, between CollaGenex Pharmaceuticals, Inc. and American Stock
Transfer & Trust Company which includes (i) the Form of Rights
Certificate and (ii) the Certificate of Designation of Series A
Participating Preferred Stock of CollaGenex Pharmaceuticals, Inc.
99.1 Press Release dated as of September 16, 1997.
99.2 Form of Stockholder Letter.
-5-
<PAGE>
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act
of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned thereunto duly authorized.
COLLAGENEX PHARMACEUTICALS, INC.
By: /s/ Brian M. Gallagher, Ph.D.
-----------------------------
Name: Brian M. Gallagher, Ph.D.
Title: President, Chief Executive Officer
and Director
September 17, 1997
-6-
<PAGE>
EXHIBIT LIST
4.1 Shareholder Protection Rights Agreement, dated as of September 15,
1997, between CollaGenex Pharmaceuticals, Inc. and American Stock
Transfer & Trust Company which includes (i) the Form of Rights
Certificate and (ii) the Certificate of Designation of Series A
Participating Preferred Stock of CollaGenex Pharmaceuticals, Inc.
99.1 Press Release dated as of September 16, 1997.
99.2 Form of Stockholder Letter.
-7-
EXECUTION COPY
--------------
================================================================================
SHAREHOLDER PROTECTION RIGHTS AGREEMENT
dated as of
September 15, 1997
between
COLLAGENEX PHARMACEUTICALS, INC.
and
AMERICAN STOCK TRANSFER & TRUST COMPANY
as Rights Agent
================================================================================
<PAGE>
TABLE OF CONTENTS
PAGE
----
ARTICLE I DEFINITIONS........................................................2
1.1 Definitions........................................................2
ARTICLE II THE RIGHTS......................................................12
2.1 Summary of Rights.................................................12
2.2 Legend on Common Stock Certificates...............................12
2.3 Exercise of Rights: Separation of Rights..........................13
2.4 Adjustments to Exercise Price: Number of Rights...................16
2.5 Date on Which Exercise is Effective...............................18
2.6 Execution, Authentication, Delivery and Dating of Rights
Certificates....................................................18
2.7 Registration, Registration of Transfer and Exchange...............19
2.8 Mutilated, Destroyed, Lost and Stolen Rights Certificates.........20
2.9 Persons Deemed Owners.............................................21
2.10 Delivery and Cancellation of Certificates........................22
2.11 Agreement of Rights Holders......................................22
ARTICLE III ADJUSTMENTS TO THE RIGHTS IN EVENT OF CERTAIN TRANSACTIONS.....23
3.1 Flip-in...........................................................23
3.2 Flip-over.........................................................27
ARTICLE IV THE RIGHTS AGENT................................................28
4.1 General...........................................................28
4.2 Merger or Consolidation or Change of Name of Rights Agent.........29
4.3 Duties of Rights Agent............................................30
4.4 Change of Rights Agent............................................33
ARTICLE V MISCELLANEOUS....................................................35
5.1 Redemption........................................................35
5.2 Expiration........................................................36
5.3 Issuance of New Rights Certificates...............................36
5.4 Supplements and Amendments........................................37
5.5 Fractional Shares.................................................39
5.6 Rights of Action..................................................39
5.7 Holder of Rights Not Deemed a Shareholder.........................40
5.8 Notice of Proposed Actions........................................40
5.9 Notices...........................................................41
5.10 Suspension of Exercisability.....................................42
5.11 Costs of Enforcement.............................................42
5.12 Successors.......................................................43
- i -
<PAGE>
TABLE OF CONTENTS
PAGE
----
5.13 Benefits of this Agreement.......................................43
5.14 Determination and Actions by the Board of Directors, etc.........43
5.15 Descriptive Headings.............................................44
5.16 Governing Law....................................................44
5.17 Counterparts.....................................................44
5.18 Severability.....................................................44
- ii -
<PAGE>
SHAREHOLDER PROTECTION RIGHTS AGREEMENT
---------------------------------------
SHAREHOLDER PROTECTION RIGHTS AGREEMENT (as amended from time to
time, this "Agreement"), dated as of September 15, 1997, between CollaGenex
Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and American
Stock Transfer & Trust Company, as Rights Agent (the "Rights Agent," which term
shall include any successor Rights Agent hereunder).
WITNESSETH:
-----------
WHEREAS, the Board of Directors of the Company has (a) authorized
and declared a dividend of one right ("'Right") in respect of each share of
Common Stock (as hereinafter defined) held of record as of the close of business
on September 26, 1997 (the "Record Time") and (b) as provided in Section 2.4,
authorized the issuance of one Right in respect of each share of Common Stock
issued after the Record Time and prior to the Separation Time (as hereinafter
defined) and, to the extent provided in Section 5.3, each share of Common Stock
issued after the Separation Time;
WHEREAS, subject to the terms and conditions hereof, each Right
entitles the holder thereof, after the Separation Time, to purchase securities
or assets of the Company (or, in certain cases, securities of certain other
entities) pursuant to the terms and subject to the conditions set forth herein;
and
WHEREAS, the Company desires to appoint the Rights Agent to act on
behalf of the Company, and the Rights Agent is willing so to act, in connection
with the issuance, transfer,
<PAGE>
exchange and replacement of Rights Certificates (as hereinafter defined), the
exercise of Rights and other matters referred to herein;
NOW THEREFORE, in consideration of the premises and the respective
agreements set forth herein, the parties hereby agree as follows:
ARTICLE I
DEFINITIONS
1.1 Definitions.
-----------
For purposes of this Agreement, the following terms have the
meanings indicated:
"Acquiring Person" shall mean any Person who is a Beneficial Owner
of more than the Specified Percentage of the outstanding shares of Common Stock;
provided, however, that the term "Acquiring Person" shall not include any Person
(i) who is the Beneficial Owner of more than the Specified Percentage (as
defined below) of the outstanding shares of Common Stock on the date of this
Agreement or who shall become the Beneficial Owner of more than the Specified
Percentage of the outstanding shares of Common Stock solely as a result of an
acquisition by the Company of shares of Common Stock until such time as any of
such Persons shall become the Beneficial Owner (other than by means of a stock
dividend or stock split) after the date hereof of an additional 1% of the
outstanding shares of Common Stock, provided, that, for the purpose of
determining whether any Person has become the Beneficial Owner of an additional
1% of the outstanding shares of Common Stock, compensatory management stock
options and other stock-based management awards issued by the Company subsequent
to the date of this Agreement shall not be included, (ii) who becomes the
Beneficial Owner of more
-2-
<PAGE>
than the Specified Percentage of the outstanding shares of Common Stock but who
acquired Beneficial Ownership of shares of Common Stock without any plan or
intention to seek or affect control of the Company, if such Person promptly
enters into an irrevocable commitment to divest, and thereafter promptly divests
(without exercising or retaining any power, including voting, with respect to
such shares), sufficient shares of Common Stock (or securities convertible into,
exchangeable into or exercisable for Common Stock) so that such Person ceases to
be the Beneficial Owner of more than the Specified Percentage of the outstanding
shares of Common Stock or (iii) who Beneficially Owns shares of Common Stock
consisting solely of one or more of (A) shares of Common Stock Beneficially
Owned pursuant to the grant or exercise of an option granted to such Person (an
"Option Holder") by the Company in connection with an agreement to merge with,
or acquire, the Company entered into prior to a Flip-in Date, (B) shares of
Common Stock (or securities convertible into, exchangeable into or exercisable
for Common Stock), Beneficially Owned by such Option Holder or its Affiliates or
Associates at the time of grant of such option, and (C) shares of Common Stock
(or securities convertible into, exchangeable into or exercisable for Common
Stock) acquired by Affiliates or Associates of such Option Holder after the time
of such grant which, in the aggregate, amount to less than 1% of the outstanding
shares of Common Stock. In addition, the Company, any wholly-owned Subsidiary
(as defined below) of the Company and any employee stock ownership or other
employee benefit plan of the Company or a wholly-owned Subsidiary of the Company
shall not be an Acquiring Person.
-3-
<PAGE>
"Affiliate" and "Associate" shall have the respective meanings
ascribed to such terms in Rule 12b-2 under the Exchange Act, as such Rule is in
effect on the date of this Agreement.
"Agreement" shall have the meaning set forth in the preamble.
A Person shall be deemed the "Beneficial Owner," and to have
"Beneficial Ownership" of, and to "Beneficially Own," any securities as to which
such Person or any of such Person's Affiliates or Associates is or may be deemed
to be the beneficial owner of pursuant to Rule 13d-3 and 13d-5 under the
Exchange Act, as such Rules are in effect on the date of this Agreement, as well
as any securities as to which such Person or any of such Person's Affiliates or
Associates has the right to become Beneficial Owner (whether such right is
exercisable immediately or only after the passage of time or the occurrence of
conditions) pursuant to any agreement, arrangement or understanding, or upon the
exercise of conversion rights, exchange rights, rights (other than the Rights),
warrants or options, or otherwise; provided, however, that a Person shall not be
deemed the "Beneficial Owner," or to have "Beneficial Ownership" of, or to
"Beneficially Own," any security (i) solely because such security has been
tendered pursuant to a tender or exchange offer made by such Person or any of
such Person's Affiliates or Associates until such tendered security is accepted
for payment or exchange or (ii) solely because such Person or any of such
Person's Affiliates or Associates has or shares the power to vote or direct the
voting of such security pursuant to a revocable proxy given in response to a
public proxy or consent solicitation made to more than ten holders of shares of
a class of stock of the Company registered under Section 12 of the Exchange Act
and pursuant to, and in accordance with, the applicable rules and regulations
under the Exchange Act, except if such power (or the
-4-
<PAGE>
arrangements relating thereto) is then reportable under Item 6 of Schedule 13D
under the Exchange Act (or any similar provision of a comparable or successor
report). Notwithstanding the foregoing, no officer or director of the Company
shall be deemed to Beneficially Own any securities of any other Person by virtue
of any actions such officer or director takes in such capacity. For purposes of
this Agreement, in determining the percentage of the outstanding shares of
Common Stock with respect to which a Person is the Beneficial Owner, all shares
as to which such Person is deemed the Beneficial Owner shall be deemed
outstanding.
"Business Day" shall mean any day other than a Saturday, Sunday or a
day on which banking institutions in The City of New York are generally
authorized or obligated by law or executive order to close.
"Close of business" on any given date shall mean 5:00 p.m. New York
City time on such date or, if such date is not a Business Day, 5:00 p.m., New
York City time, on the next succeeding Business Day.
"Common Stock" shall mean the shares of Common Stock, $0.01 par
value, of the Company.
"Company" shall have the meaning set forth in the preamble.
"Disinterested Directors" shall mean (i) any member of the Board of
Directors of the Company, while such Person is a member of the Board, who is not
an Acquiring Person or an Affiliate or Associate of an Acquiring Person, or a
representative of an Acquiring Person or any such Affiliate or Associate, and
was a member of the Board prior to the time that the Acquiring Person became an
Acquiring Person, or (ii) any Person who subsequently becomes a member of the
Board to fill a vacancy created by an increase in the size of the Board, while
such Person is a
-5-
<PAGE>
member of the Board, who is not an Acquiring Person or an Affiliate or Associate
of an Acquiring Person, or a representative of an Acquiring Person or of any
such Affiliate or Associate, if such Person's nomination for election by the
shareholders or election to the Board is recommended or approved by a majority
of the Disinterested Directors, or (iii) any successor of a Disinterested
Director who is not an Acquiring Person or an Affiliate or Associate of an
Acquiring Person, or a representative of an Acquiring Person or an Affiliate or
Associate of an Acquiring Person, or a representative of an Acquiring Person or
of any such Affiliate or Associate, if such Person's nomination for election by
the shareholders or election to the Board is recommended or approved by a
majority of the Disinterested Directors.
"Election to Exercise" shall have the meaning set forth in
Section 2.3(d) hereof.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
"Exchange Ratio" shall have the meaning set forth in Section
3.1(c) hereof.
"Exchange Time" shall mean the time at which the right to exercise
the Rights shall terminate pursuant to Section 3.1(c) hereof.
"Exercise Price" shall mean, as of any date, the price at which a
holder may purchase the securities issuable upon exercise of one whole Right.
Until adjustment thereof in accordance with the terms hereof, the Exercise Price
shall equal $65.00.
"Expansion Factor" shall have the meaning set forth in Section
2.4(a) hereof.
"Expiration Time" shall mean the earliest of (i) the Exchange Time,
(ii) the Redemption Time, (iii) the close of business on the tenth anniversary
of the Record Time and (iv) immediately prior to the effective time of a
consolidation, merger or share exchange of the Company (A) into another
corporation or (B) with another corporation in which the Company is
-6-
<PAGE>
the surviving corporation but Common Stock is converted into cash and/or
securities of another corporation, in either case pursuant to an agreement
entered into by the Company prior to a Stock Acquisition Date.
"'Flip-in Date" shall mean any Stock Acquisition Date or such
earlier or later date as the Board of Directors of the Company may from time to
time fix by resolution adopted prior to the Flip-in Date that would otherwise
have occurred.
"Flip-over Entity," for purposes of Section 3.2, shall mean (i) in
the case of a Flip-over Transaction or Event described in clause (i) of the
definition thereof, the Person issuing any securities into which shares of
Common Stock are being converted or exchanged and, if no such securities are
being issued, the other party to such Flip-over Transaction or Event and (ii) in
the case of a Flip-over Transaction or Event referred to in clause (ii) of the
definition thereof, the Person receiving the greatest portion of (A) the assets
or (B) the operating income or cash flow being transferred in such Flip-over
Transaction or Event, provided in all cases if such Person is a Subsidiary of a
corporation, the parent corporation shall be the Flip-Over Entity.
"Flip-over Stock" shall mean the capital stock (or similar equity
interest) with the greatest voting power in respect of the election of directors
(or other persons similarly responsible for direction of the business and
affairs) of the Flip-Over Entity.
"Flip-over Transaction or Event" shall mean a transaction or series
of transactions after a Flip-in Date in which, directly or indirectly, (i) the
Company shall consolidate or merge or participate in a share exchange with any
other Person if, at the time of the consolidation, merger or share exchange or
at the time the Company enters into any agreement with respect to any such
consolidation, merger or share exchange, the Acquiring Person controls the Board
of Directors of
-7-
<PAGE>
the Company and either (A) any term of or arrangement concerning the treatment
of shares of capital stock in such consolidation, merger or share exchange
relating to the Acquiring Person is not identical to the terms and arrangements
relating to other holders of the Common Stock or (B) the Person with whom the
transaction or series of transactions occurs is the Acquiring Person or an
Affiliate or Associate of the Acquiring Person or (ii) the Company shall sell or
otherwise transfer (or one or more of its Subsidiaries shall sell or otherwise
transfer) assets (A) aggregating more than 50% of the assets (measured by either
book value or fair market value) or (B) generating more than 50% of the
operating income or cash flow, of the Company and its Subsidiaries (taken as a
whole) to any Person (other than the Company or one or more of its wholly-owned
Subsidiaries) or to two or more such Persons which are Affiliates or Associates
or otherwise acting in concert, if, at the time of the entry by the Company (or
any such Subsidiary) into an agreement with respect to such sale or transfer of
assets, the Acquiring Person controls the Board of Directors of the Company. For
the purposes hereof, an Acquiring Person shall be deemed to "control" the
Company's Board of Directors when, following a Flip-in Date, the persons who
were directors of the Company (or persons nominated and/or appointed as
directors by vote of a majority of such persons) before the Stock Acquisition
Date shall cease to constitute a majority of the Company's Board of Directors.
"Market Price" per share of any securities on any date shall mean
the average of the daily closing prices per share of such securities (determined
as described below) on each of the 20 consecutive Trading Days (as defined
below) through and including the Trading Day immediately preceding such date;
provided, however, that if an event of a type analogous to any of the events
described in Section 2.4 hereof shall have caused the closing prices used to
-8-
<PAGE>
determine the Market Price on any Trading Days during such period of 20 Trading
Days not to be fully comparable with the closing price on such date, each such
closing price so used shall be appropriately adjusted in order to make it fully
comparable with the closing price on such date. The closing price per share of
any securities on any date shall be the last reported sale price, regular way,
or, in case no such sale takes place or is quoted on such date, the average of
the closing bid and asked prices, regular way, for each share of such
securities, in either case as reported in the principal consolidated transaction
reporting system with respect to securities listed or admitted to trading on the
New York Stock Exchange, Inc. or, if the securities are not listed or admitted
to trading on the New York Stock Exchange, Inc., as reported in the principal
consolidated transaction reporting system with respect to securities listed on
the principal national securities exchange on which the securities are listed or
admitted to trading or, if the securities are not listed or admitted to trading
on any national securities exchange, as reported by Nasdaq, or, if on any such
date the securities are not listed or admitted to trading on any national
securities exchange or quoted on Nasdaq, the average of the closing bid and
asked prices as furnished by a professional market maker making a market in the
securities selected by the Board of Directors of the Company; provided, however,
that if on any such date the securities are not listed or admitted to trading on
a national securities exchange or traded in the over-the-counter market, the
closing price per share of such securities on such date shall mean the fair
value per share of securities on such date as determined in good faith by the
Board of Directors of the Company, after consultation with a nationally
recognized investment banking firm, and set forth in a certificate delivered to
the Rights Agent.
-9-
<PAGE>
"Option Holder" shall have the meaning set forth in the
definition of Acquiring Person.
"Person" shall mean any individual, firm, partnership, association,
group (as such term is used in Rule 13d-5 under the Securities Exchange Act of
1934, as such Rule is in effect on the date of this Agreement), corporation or
other entity.
"Preferred Stock" shall mean the Series A Participating Preferred
Stock, no par value, of the Company created by a Certificate of Designation in
substantially the form set forth in Exhibit B hereto.
"Record Time" shall have the meaning set forth in the Recitals.
"Redemption Price" shall mean an amount equal to one cent, $0.01.
"Redemption Time" shall mean the time at which the right to exercise
the Rights shall terminate pursuant to Section 5.1 hereof.
"Right" shall have the meaning set forth in the Recitals.
"Rights Agent" shall have the meaning set forth in the Preamble.
"Rights Certificate" shall have the meaning set forth in Section
2.3(c) hereof.
"Rights Register" shall have the meaning set forth in Section
2.7(a) hereof.
"Securities Act" shall mean the Securities Act of 1933, as
amended.
"Separation Time" shall mean the close of business on the earlier of
(i) the tenth business day (or such later date as the Board of Directors of the
Company may from time to time fix by resolution adopted prior to the Separation
Time that would otherwise have occurred) after the date on which any Person
commences a tender or exchange offer which, if consummated, would result in such
Persons becoming an Acquiring Person and (ii) the tenth business day (or
-10-
<PAGE>
such later date as the Board of Directors of the Company may from time to time
fix by resolution adopted prior to the Separation Time that would otherwise have
occurred) after the Flip-in Date; provided, that if the foregoing results in the
Separation Time being prior to the Record Time, the Separation Time shall be the
Record Time and provided further, that if any tender or exchange offer referred
to in clause (i) of this paragraph is canceled, terminated or otherwise
withdrawn prior to the Separation Time without the purchase of any shares of
Common Stock pursuant thereto, such offer shall be deemed, for purposes of this
paragraph, never to have been made.
"Specified Percentage" shall mean 20%.
"Stock Acquisition Date" shall mean the first date of public
announcement by the Company (by any means) or by an Acquiring Person (including
by means of filing a Schedule 13D or Schedule 13G under the Exchange Act (or any
comparable or successor report or schedule) or an amendment thereto) that a
Person has become an Acquiring Person.
"Subsidiary" of any specified Person shall mean any corporation or
other entity of which a majority of the voting power of the equity securities or
a majority of the equity interest is Beneficially Owned, directly or indirectly,
by such Person.
"Trading Day," when used with respect to any securities, shall mean
a day on which the New York Stock Exchange, Inc. is open for the transaction of
business or, if such securities are not listed or admitted to trading on the New
York Stock Exchange, Inc., a day on which the principal national securities
exchange on which such securities are listed or admitted to trading is open for
the transaction of business or, if such securities are not listed or admitted to
trading on any national securities exchange, a Business Day.
-11-
<PAGE>
ARTICLE II
THE RIGHTS
2.1 Summary of Rights.
-----------------
As soon as practicable after the Record Time, the Company will mail
a letter summarizing the terms of the Rights to each holder of record of Common
Stock as of the Record Time, at such holder's address as shown by the records of
the Company.
2.2 Legend on Common Stock Certificates.
-----------------------------------
Certificates for the Common Stock issued after the Record Time but
prior to the Separation Time shall evidence one Right for each share of Common
Stock represented thereby and shall have impressed on, printed on, written on or
otherwise affixed to them the following legend:
Until the Separation Time (as defined in the Rights Agreement referred to
below), this certificate also evidences and entitles the holder hereof to
certain Rights as set forth in a Shareholder Protection Rights Agreement,
dated as of September 15, 1997 (as such may be amended from time to time,
the "Rights Agreement"), between CollaGenex Pharmaceuticals, Inc. (the
"Company") and American Stock Transfer & Trust Company, as Rights Agent,
the terms of which are hereby incorporated herein by reference and a copy
of which is on file at the principal executive offices of the Company.
Under certain circumstances, as set forth in the Rights Agreement, such
Rights may be redeemed, may become exercisable for securities or assets of
the Company or securities of another entity, may be exchanged for shares
of Common Stock or other securities or assets of the Company, may expire,
may become void (if they are "Beneficially Owned" by an "Acquiring Person"
or an Affiliate or Associate thereof, as such terms are defined in the
Rights Agreement, or by any transferee of any of the foregoing) or may be
evidenced by separate certificates and may no longer be evidenced by this
certificate. The Company will mail or arrange for the mailing of a copy of
the Rights Agreement to the holder of this certificate without charge
after the receipt of a written request therefor.
-12-
<PAGE>
Certificates representing shares of Common Stock that are issued and outstanding
at the Record Time shall evidence one Right for each share of Common Stock
evidenced thereby notwithstanding the absence of the foregoing legend.
2.3 Exercise of Rights; Separation of Rights.
----------------------------------------
(a) Subject to Sections 3.1, 5.1 and 5.10 and subject to adjustment
as herein set forth, each Right will entitle the holder thereof, after the
Separation Time and prior to the Expiration Time, to purchase, for the Exercise
Price, one one-hundredth of a share of Preferred Stock.
(b) Until the Separation Time, (i) no Right may be exercised and
(ii) each Right will be evidenced by the certificate for the associated share of
Common Stock (together, in the case of certificates issued prior to the Record
Time, with the letter mailed to the record holder thereof pursuant to Section
2.1) and will be transferable only together with, and will be transferred by a
transfer (whether with or without such letter) of, such associated share.
(c) Subject to the terms and conditions hereof, after the Separation
Time and prior to the Expiration Time, the Rights (i) may be exercised and (ii)
may be transferred independent of shares of Common Stock. Promptly following the
Separation Time, the Rights Agent will mail to each holder of record of Common
Stock as of the Separation Time (other than any Person whose Rights have become
void pursuant to Section 3.1(b)), at such holder's address as shown by the
records of the Company (the Company hereby agreeing to furnish copies of such
records to the Rights Agent for this purpose), (x) a certificate (a "Rights
Certificate") in substantially the form of Exhibit A hereto appropriately
completed, representing the number of Rights held by
-13-
<PAGE>
such holder at the Separation Time and having such marks of identification or
designation and such legends, summaries or endorsements printed thereon as the
Company may deem appropriate and as are not inconsistent with the provisions of
this Agreement, or as may be required to comply with any law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any national
securities exchange or quotation system on which the Rights may from time to
time be listed or traded, or to conform to usage, and (y) a disclosure statement
describing the Rights.
(d) Subject to the terms and conditions hereof, Rights may be
exercised on any Business Day after the Separation Time and prior to the
Expiration Time by submitting to the Rights Agent the Rights Certificate
evidencing such Rights with an Election to Exercise (an "Election to Exercise")
substantially in the form attached to the Rights Certificate duly completed,
accompanied by payment in cash, or by certified or official bank check or money
order payable to the order of the Company, of a sum equal to the Exercise Price
multiplied by the number of Rights being exercised and a sum sufficient to cover
any transfer tax or charge which may be payable in respect of any transfer
involved in the transfer or delivery of Rights Certificates or the issuance or
delivery of certificates for shares or depositary receipts (or both) in a name
other than that of the holder of the Rights being exercised.
(e) Upon receipt of a Rights Certificate, with an Election to
Exercise accompanied by payment as set forth in Section 2.3(d), and subject to
the terms and conditions hereof, the Rights Agent will thereupon promptly (i)(A)
requisition from a transfer agent stock certificates evidencing such number of
shares or other securities to be purchased (the Company hereby irrevocably
authorizing its transfer agents to comply with all such requisitions) and (B) if
the
-14-
<PAGE>
Company elects pursuant to Section 5.5 not to issue certificates representing
fractional shares, requisition from the depositary selected by the Company
depositary receipts representing the fractional shares to be purchased or
requisition from the Company the amount of cash to be paid in lieu of fractional
shares in accordance with Section 5.5 and (ii) after receipt of such
certificates, depositary receipts and/or cash, deliver the same to or upon the
order of the registered holder of such Rights Certificate, registered (in the
case of certificates or depositary receipts) in such name or names as may be
designated by such holder.
(f) In case the holder of any Rights shall exercise less than all
the Rights evidenced by such holder's Rights Certificate, a new Rights
Certificate evidencing the Rights remaining unexercised will be issued by the
Rights Agent to such holder or to such holder's duly authorized assigns.
(g) The Company covenants and agrees that it will (i) take all such
action as may be necessary to ensure that all shares delivered upon exercise of
Rights shall, at the time of delivery of the certificates for such shares
(subject to payment of the Exercise Price), be duly and validly authorized,
executed, issued and delivered and fully paid and nonassessable; (ii) take all
such action as may be necessary to comply with any applicable requirements of
the Securities Act or the Exchange Act, and the rules and regulations
thereunder, and any other applicable law, rule or regulation, in connection with
the issuance of any shares upon exercise of Rights; and (iii) pay when due and
payable any and all federal and state transfer taxes and charges which may be
payable in respect of the original issuance or delivery of the Rights
Certificates or of any shares issued upon the exercise of Rights, provided, that
the Company shall not be required to pay any transfer tax or charge which may be
payable in respect of any transfer involved in the transfer or
-15-
<PAGE>
delivery of Rights Certificates or the issuance or delivery of certificates for
shares in a name other than that of the holder of the Rights being transferred
or exercised.
2.4 Adjustments to Exercise Price; Number of Rights.
-----------------------------------------------
(a) In the event the Company shall at any time after the Record Time
and prior to the Separation Time (i) declare or pay a dividend on Common Stock
payable in Common Stock, (ii) subdivide the outstanding Common Stock or (iii)
combine the outstanding Common Stock into a smaller number of shares of Common
Stock, (x) the Exercise Price in effect after such adjustment will be equal to
the Exercise Price in effect immediately prior to such adjustment divided by the
number of shares of Common Stock (the "Expansion Factor") that a holder of one
share of Common Stock immediately prior to such dividend, subdivision or
combination would hold thereafter as a result thereof and (y) each Right held
prior to such adjustment will become that number of Rights equal to the
Expansion Factor, and the adjusted number of Rights will be deemed to be
distributed among the shares of Common Stock with respect to which the original
Rights were associated (if they remain outstanding) and the shares issued in
respect of such dividend, subdivision or combination, so that each such share of
Common Stock will have exactly one Right associated with it. Each adjustment
made pursuant to this paragraph shall be made as of the payment or effective
date for the applicable dividend, subdivision or combination.
In the event the Company shall at any time after the Record Time and
prior to the Separation Time issue any shares of Common Stock otherwise than in
a transaction referred to in the preceding paragraph, each such share of Common
Stock so issued shall automatically have one new Right associated with it, which
Right shall be evidenced by the certificate representing
-16-
<PAGE>
such share. To the extent provided in Section 5.3, Rights shall be issued by the
Company in respect of shares of Common Stock that are issued or sold by the
Company after the Separation Time.
(b) In the event the Company shall at any time after the Record Time
and prior to the Separation Time issue or distribute any securities or assets in
respect of, in lieu of or in exchange for Common Stock (other than pursuant to a
regular periodic cash dividend or a dividend paid solely in Common Stock)
whether by dividend, in a reclassification or recapitalization (including any
such transaction involving a merger, consolidation or share exchange), or
otherwise, the Company shall make such adjustments, if any, in the Exercise
Price, number of Rights and/or securities or other property purchasable upon
exercise of Rights as the Board of Directors of the Company, in its sole
discretion, may deem to be appropriate under the circumstances in order to
adequately protect the interests of the holders of Rights generally, and the
Company and the Rights Agent shall amend this Agreement as necessary to provide
for such adjustments.
(c) Each adjustment to the Exercise Price made pursuant to this
Section 2.4 shall be calculated to the nearest cent. Whenever an adjustment to
the Exercise Price is made pursuant to this Section 2.4, the Company shall (i)
promptly prepare a certificate setting forth such adjustment and a brief
statement of the facts accounting for such adjustment and (ii) promptly file
with the Rights Agent and with each transfer agent for the Common Stock a copy
of such certificate.
(d) Rights certificates shall represent the securities purchasable
under the terms of this Agreement, including any adjustment or change in the
securities purchasable upon exercise
-17-
<PAGE>
of the Rights, even though such certificates may continue to express the
securities purchasable at the time of issuance of the initial Rights
Certificates.
2.5 Date on Which Exercise is Effective.
-----------------------------------
Each person in whose name any certificate for shares is issued upon
the exercise of Rights shall for all purposes be deemed to have become the
holder of record of the shares represented thereby on the date upon which the
Rights Certificate evidencing such Rights was duly surrendered and payment of
the Exercise Price for such Rights (and any applicable taxes and other
governmental charges payable by the exercising holder hereunder) was made;
provided, however, that if the date of such surrender and payment is a date upon
which the stock transfer books of the Company are closed, such person shall be
deemed to have become the record holder of such shares on, and such certificate
shall be dated, the next succeeding Business Day on which the stock transfer
books of the Company are open.
2.6 Execution, Authentication, Delivery and Dating of Rights
Certificates.
--------------------------------------------------------
(a) The Rights Certificates shall be executed on behalf of the
Company by its Chairman of the Board, President or one of its Vice Presidents,
under its corporate seal reproduced thereon attested by its Secretary or one of
its Assistant Secretaries. The signature of any of these officers on the Rights
Certificates may be manual or facsimile.
Rights Certificates bearing the manual or facsimile signatures of
individuals who were at any time the proper officers of the Company shall bind
the Company, notwithstanding that such individuals or any of them have ceased to
hold such offices prior to the counter-signature and delivery of such Rights
Certificates.
-18-
<PAGE>
Promptly after the Company learns of the Separation Time, the
Company will notify the Rights Agent of such Separation Time and will deliver
Rights Certificates executed by the Company to the Rights Agent for
counter-signature, and, subject to Section 3.1(b), the Rights Agent shall
manually countersign and deliver such Rights Certificates to the holders of the
Rights pursuant to Section 2.3(c) hereof. No Rights Certificate shall be valid
for any purpose unless manually countersigned by the Rights Agent.
(b) Each Rights Certificate shall be dated the date of counter-
signature thereof.
2.7 Registration, Registration of Transfer and Exchange.
---------------------------------------------------
(a) After the Separation Time, the Company will cause to be kept a
register (the "Rights Register") in which, subject to such reasonable
regulations as it may prescribe, the Company will provide for the registration
and transfer of Rights. The Rights Agent is hereby appointed "Rights Registrar"
for the purpose of maintaining the Rights Register for the Company and
registering Rights and transfers of Rights after the Separation Time as herein
provided. In the event that the Rights Agent shall cease to be the Rights
Registrar, the Rights Agent will have the right to examine the Rights Register
at all reasonable times after the Separation Time.
After the Separation Time and prior to the Expiration Time, upon
surrender for registration of transfer or exchange of any Rights Certificate,
and subject to the provisions of Section 2.7(c) and (d), the Company will
execute, and the Rights Agent will countersign and deliver, in the name of the
holder or the designated transferee or transferees, as required pursuant to the
holder's instructions, one or more new Rights Certificates evidencing the same
aggregate number of Rights as did the Rights Certificate so surrendered.
-19-
<PAGE>
(b) Except as otherwise provided in Section 3.1(b), all Rights
issued upon any registration of transfer or exchange of Rights Certificates
shall be the valid obligations of the Company, and such Rights shall be entitled
to the same benefits under this Agreement as the Rights surrendered upon such
registration of transfer or exchange.
(c) Every Rights Certificate surrendered for registration of
transfer or exchange shall be duly endorsed, or be accompanied by a written
instrument of transfer in form satisfactory to the Company or the Rights Agent,
as the case may be, duly executed by the holder thereof or such holder's
attorney duly authorized in writing. As a condition to the issuance of any new
Rights Certificate under this Section 2.7, the Company may require the payment
of a sum sufficient to cover any tax or other governmental charge that may be
imposed in relation thereto.
(d) The Company shall not be required to register the transfer or
exchange of any Rights after such Rights have become void under Section 3.1(b),
been exchanged under Section 3.1(c) or been redeemed under Section 5.1.
2.8 Mutilated, Destroyed, Lost and Stolen Rights Certificates.
---------------------------------------------------------
(a) If any mutilated Rights Certificate is surrendered to the Rights
Agent prior to the Expiration Time, then, subject to Sections 3.1(b), 3.1(c) and
5.1, the Company shall execute and the Rights Agent shall countersign and
deliver in exchange therefor a new Rights Certificate evidencing the same number
of Rights as did the Rights Certificate so surrendered.
(b) If there shall be delivered to the Company and the Rights Agent
prior to the Expiration Time (i) evidence to their satisfaction of the
destruction, loss or theft of any Rights Certificate and (ii) such security or
indemnity as may be required by them to save each of them
-20-
<PAGE>
and any of their agents harmless, then, subject to Sections 3.1(b), 3.1(c) and
5.1 and in the absence of notice to the Company or the Rights Agent that such
Rights Certificate has been acquired by a bona fide purchaser, the Company shall
execute, and upon the Company's request the Rights Agent shall countersign and
deliver, in lieu of any such destroyed, lost or stolen Rights Certificate, a new
Rights Certificate evidencing the same number of Rights as did the Rights
Certificate so destroyed, lost or stolen.
(c) As a condition to the issuance of any new Rights Certificate
under this Section 2.8, the Company may require the payment of a sum sufficient
to cover any tax or other governmental charge that may be imposed in relation
thereto and any other expenses (including the fees and expenses of the Rights
Agent) connected therewith.
(d) Every new Rights Certificate issued pursuant to this Section 2.8
in lieu of any destroyed, lost or stolen Rights Certificate shall evidence an
original additional contractual obligation of the Company, whether or not the
destroyed, lost or stolen Rights Certificate shall be at any time enforceable by
anyone, and, subject to Section 3.1(b) shall be entitled to all the benefits of
this Agreement equally and proportionately with any and all other Rights duly
issued hereunder.
2.9 Persons Deemed Owners.
---------------------
Prior to due presentment of a Rights Certificate (or, prior to the
Separation Time, the associated Common Stock certificate) for registration of
transfer, the Company, the Rights Agent and any agent of the Company or the
Rights Agent may deem and treat the person in whose name such Rights Certificate
(or, prior to the Separation Time, such Common Stock
-21-
<PAGE>
certificate) is registered as the absolute owner thereof and of the Rights
evidenced thereby for all purposes whatsoever, including the payment of the
Redemption Price, and neither the Company nor the Rights Agent shall be affected
by any notice to the contrary. As used in this Agreement, unless the context
otherwise requires, the term "holder" of any Rights shall mean the registered
holder of such Rights (or, prior to the Separation Time, the associated shares
of Common Stock).
2.10 Delivery and Cancellation of Certificates.
-----------------------------------------
All Rights Certificates surrendered upon exercise or for
registration of transfer or exchange shall, if surrendered to any person other
than the Rights Agent, be delivered to the Rights Agent and, in any case, shall
be promptly canceled by the Rights Agent. The Company may at any time deliver to
the Rights Agent for cancellation any Rights Certificates previously
countersigned and delivered hereunder which the Company may have acquired in any
manner whatsoever, and all Rights Certificates so delivered shall be promptly
canceled by the Rights Agent. No Rights Certificates shall be countersigned in
lieu of or in exchange for any Rights Certificates canceled as provided in this
Section 2.10, except as expressly permitted by this Agreement. The Rights Agent
shall destroy all canceled Rights Certificates and deliver a certificate of
destruction to the Company.
2.11 Agreement of Rights Holders.
---------------------------
Every holder of Rights by accepting the same consents and agrees
with the Company and the Rights Agent and with every other holder of Rights
that:
(a) prior to the Separation Time, each Right will be transferable
only together with, and will be transferred by a transfer of, the associated
share of Common Stock;
-22-
<PAGE>
(b) after the Separation Time, the Rights Certificates will be
transferable only on the Rights Register as provided herein;
(c) prior to due presentment of a Rights Certificate (or, prior to
the Separation Time, the associated Common Stock certificate) for registration
of transfer, the Company, the Rights Agent and any agent of the Company or the
Rights Agent may deem and treat the person in whose name the Rights Certificate
(or, prior to the Separation Time, the associated Common Stock certificate) is
registered as the absolute owner thereof and of the Rights evidenced thereby for
all purposes whatsoever, and neither the Company nor the Rights Agent shall be
affected by any notice to the contrary;
(d) Rights beneficially owned by certain Persons will, under the
circumstances set forth in Section 3.1(b), become void; and
(e) this Agreement may be supplemented or amended from time to time
pursuant to Section 2.4(b) or 5.4 hereof.
ARTICLE III
ADJUSTMENTS TO THE RIGHTS IN
THE EVENT OF CERTAIN TRANSACTIONS
3.1 Flip-in.
-------
(a) In the event that prior to the Expiration Time a Flip-in Date
shall occur, except as provided in this Section 3.1, each Right shall constitute
the right to purchase from the Company, upon exercise thereof in accordance with
the terms hereof (but subject to Section 5.10), that number of shares of Common
Stock having an aggregate Market Price on the Stock
-23-
<PAGE>
Acquisition Date equal to twice the Exercise Price for an amount in cash equal
to the Exercise Price (such right to be appropriately adjusted in order to
protect the interests of the holders of Rights generally in the event that on or
after such Stock Acquisition Date an event of a type analogous to any of the
events described in Section 2.4(a) or (b) shall have occurred with respect to
the Common Stock).
(b) Notwithstanding the foregoing, any Rights that are or were
Beneficially Owned on or after the Stock Acquisition Date by an Acquiring Person
or an Affiliate or Associate thereof or by any transferee, direct or indirect,
of any of the foregoing shall become void and any holder of such Rights
(including transferees) shall thereafter have no right to exercise or transfer
such Rights under any provision of this Agreement. If any Rights Certificate is
presented for assignment or exercise and the Person presenting the same will not
complete the certification set forth at the end of the form of assignment or
notice of election to exercise and provide such additional evidence of the
identity of the Beneficial Owner and its Affiliates and Associates (or former
Beneficial Owners and their Affiliates and Associates) as the Company shall
reasonably request, then the Company shall be entitled conclusively to deem the
Beneficial Owner thereof to be an Acquiring Person or an Affiliate or Associate
thereof or a transferee of any of the foregoing and accordingly will deem the
Rights evidenced thereby to be void and not transferable or exercisable.
(c) The Board of Directors of the Company may, at its option, at any
time after a Flip-in Date and prior to the time that an Acquiring Person becomes
the Beneficial Owner of more than 50% of the outstanding shares of Common Stock
elect to exchange all (but not less than all) of the then outstanding Rights
(which shall not include Rights that have become void
-24-
<PAGE>
pursuant to the provisions of Section 3.1(b)) for shares of Common Stock at an
exchange ratio of one share of Common Stock per Right, appropriately adjusted in
order to protect the interests of holders of Rights generally in the event that
after the Separation Time an event of a type analogous to any of the events
described in Section 2.4(a) or (b) shall have occurred with respect to the
Common Stock (such exchange ratio, as adjusted from time to time, being
hereinafter referred to as the "Exchange Ratio").
Immediately upon the action of the Board of Directors of the Company
electing to exchange the Rights, without any further action and without any
notice, the right to exercise the Rights will terminate and each Right (other
than Rights that have become void pursuant to Section 3.1(b)) will thereafter
represent only the right to receive a number of shares of Common Stock equal to
the Exchange Ratio. Promptly after the action of the Board of Directors electing
to exchange the Rights, the Company shall give notice thereof (specifying the
steps to be taken to receive shares of Common Stock in exchange for Rights) to
the Rights Agent and the holders of the Rights (other than Rights that have
become void pursuant to Section 3.1(b)) outstanding immediately prior thereto by
mailing such notice in accordance with Section 5.9.
Each Person in whose name any certificate for shares is issued upon
the exchange of Rights pursuant to this Section 3.1(c) or Section 3.1(d) shall
for all purposes be deemed to have become the holder of record of the shares
represented thereby on, and such certificate shall be dated, the date upon which
the Rights Certificate evidencing such Rights was duly surrendered and payment
of any applicable taxes and other governmental charges payable by the holder was
made; provided, however, that if the date of such surrender and payment is a
date upon which the stock transfer books of the Company are closed, such Person
shall be deemed to
-25-
<PAGE>
have become the record holder of such shares on, and such certificate shall be
dated, the next succeeding Business Day on which the stock transfer books of the
Company are open.
(d) Whenever the Company shall become obligated under Section 3.1(a)
or (c) to issue shares of Common Stock upon exercise of or in exchange for
Rights, the Company, at its option, may substitute therefor shares of Preferred
Stock, at a ratio of one one-hundredth of a share of Preferred Stock for each
share of Common Stock so issuable.
(e) In the event that there shall not be sufficient treasury shares
or authorized but unissued shares of Common Stock or Preferred Stock of the
Company to permit the exercise or exchange in full of the Rights in accordance
with Section 3.1(a) or (c), and the Company elects not to, or is otherwise
unable to, make the exchange referred to in Section 3.1(c), the Company shall
either (i) call a meeting of shareholders seeking approval to cause sufficient
additional shares to be authorized (provided that if such approval is not
obtained the Company will take the action specified in clause (ii) of this
sentence) or (ii) take such action as shall be necessary to ensure and provide,
to the extent permitted by applicable law and any agreements or instruments in
effect on the Stock Acquisition Date to which it is a party, that each Right
shall thereafter constitute the right to receive, (x) at the Company's option,
either (A) in return for the Exercise Price, debt or equity securities or other
assets (or a combination thereof) having a fair value equal to twice the
Exercise Price, or (B) without payment of consideration (except as otherwise
required by applicable law), debt or equity securities or other assets (or a
combination thereof) having a fair value equal to the Exercise Price, or (y) if
the Board of Directors of the Company elects to exchange the Rights in
accordance with Section 3.1(c), debt or equity securities or other assets (or a
combination thereof) having a fair value equal to the product of the Market
Price of a
-26-
<PAGE>
share of Common Stock on the Flip-in Date times the Exchange Ratio in effect on
the Flip-in Date, where in any case set forth in (x) or (y) above the fair value
of such debt or equity securities or other assets shall be as determined in good
faith by the Board of Directors of the Company, after consultation with a
nationally recognized investment banking firm.
3.2 Flip-over.
---------
(a) Prior to the Expiration Time, the Company shall not enter into
any agreement with respect to, consummate or permit to occur any Flip-over
Transaction or Event unless and until it shall have entered into a supplemental
agreement with the Flip-over Entity, for the benefit of the holders of the
Rights, providing that, upon consummation or occurrence of the Flip-over
Transaction or Event (i) each Right shall thereafter constitute the right to
purchase from the Flip-over Entity, upon exercise thereof in accordance with the
terms hereof, that number of shares of Flip-over Stock of the Flip-over Entity
having an aggregate Market Price on the date of consummation or occurrence of
such Flip-over Transaction or Event equal to twice the Exercise Price for an
amount in cash equal to the Exercise Price (such right to be appropriately
adjusted in order to protect the interests of the holders of Rights generally in
the event that after such date of consummation or occurrence an event of a type
analogous to any of the events described in Section 2.4(a) or (b) shall have
occurred with respect to the Flip-over Stock) and (ii) the Flip-over Entity
shall thereafter be liable for, and shall assume, by virtue of such Flip-over
Transaction or Event and such supplemental agreement, all the obligations and
duties of the Company pursuant to this Agreement. The provisions of this Section
3.2 shall apply to successive Flip-over Transactions or Events.
-27-
<PAGE>
(b) Prior to the Expiration Time, unless the Rights will be redeemed
pursuant to Section 5.1 hereof in connection therewith, the Company shall not
enter into any agreement with respect to, consummate or permit to occur any
Flip-over Transaction or Event if at the time thereof there are any rights,
warrants or securities outstanding or any other arrangements, agreements or
instruments that would eliminate or otherwise diminish in any material respect
the benefits intended to be afforded by this Rights Agreement to the holders of
Rights upon consummation of such transaction.
ARTICLE IV
THE RIGHTS AGENT
4.1 General.
-------
(a) The Company hereby appoints the Rights Agent to act as agent for
the Company in accordance with the terms and conditions hereof, and the Rights
Agent hereby accepts such appointment. The Company agrees to pay to the Rights
Agent reasonable compensation for all services rendered by it hereunder and,
from time to time, on demand of the Rights Agent, its reasonable expenses and
counsel fees and other disbursements incurred in the administration and
execution of this Agreement and the exercise and performance of its duties
hereunder. The Company also agrees to indemnify the Rights Agent for, and to
hold it harmless against, any loss, liability, or expense, incurred without
negligence, bad faith or willful misconduct on the part of the Rights Agent, for
anything done or omitted to be done by the Rights Agent in connection with the
acceptance and administration of this Agreement, including the costs and
expenses of defending against any claim of liability.
-28-
<PAGE>
(b) The Rights Agent shall be protected and shall incur no liability
for or in respect of any action taken, suffered or omitted by it in connection
with its administration of this Agreement in reliance upon any certificate for
securities purchasable upon exercise of Rights, Rights Certificate, certificate
for other securities of the Company, instrument of assignment or transfer, power
of attorney, endorsement, affidavit, letter, notice, direction, consent,
certificate, statement, or other paper or document believed by it to be genuine
and to be signed, executed and, where necessary, verified or acknowledged, by
the proper person or persons.
4.2 Merger or Consolidation or Change of Name of Rights Agent.
---------------------------------------------------------
(a) Any corporation into which the Rights Agent or any successor
Rights Agent may be merged or with which it may be consolidated, or any
corporation resulting from any merger or consolidation to which the Rights Agent
or any successor Rights Agent is a party, or any corporation succeeding to the
shareholder services business of the Rights Agent or any successor Rights Agent,
will be the successor to the Rights Agent under this Agreement without the
execution or filing of any paper or any further act on the part of any of the
parties hereto, provided that such corporation would be eligible for appointment
as a successor Rights Agent under the provisions of Section 4.4 hereof. In case
at the time such successor Rights Agent succeeds to the agency created by this
Agreement any of the Rights Certificates have been countersigned but not
delivered, any such successor Rights Agent may adopt the counter-signature of
the predecessor Rights Agent and deliver such Rights Certificates so
countersigned; and in case at that time any of the Rights Certificates have not
been countersigned, any successor Rights Agent may countersign such Rights
Certificates either in the name of the predecessor
-29-
<PAGE>
Rights Agent or in the name of the successor Rights Agent; and in all such cases
such Rights Certificates will have the full force provided in the Rights
Certificates and in this Agreement.
(b) In case at any time the name of the Rights Agent is changed and
at such time any of the Rights Certificates shall have been countersigned but
not delivered, the Rights Agent may adopt the counter-signature under its prior
name and deliver Rights Certificates so countersigned; and in case at that time
any of the Rights Certificates shall not have been countersigned, the Rights
Agent may countersign such Rights Certificates either in its prior name or in
its changed name; and in all such cases such Rights Certificates shall have the
full force provided in the Rights Certificates and in this Agreement.
4.3 Duties of Rights Agent.
----------------------
The Rights Agent undertakes the duties and obligations imposed by
this Agreement upon the following terms and conditions, by all of which the
Company and the holders of Rights Certificates, by their acceptance thereof,
shall be bound:
(a) The Rights Agent may consult with legal counsel (who may be
legal counsel for the Company), and the opinion of such counsel will be full and
complete authorization and protection to the Rights Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion.
(b) Whenever in the performance of its duties under this Agreement
the Rights Agent deems it necessary or desirable that any fact or matter be
proved or established by the Company prior to taking or suffering any action
hereunder, such fact or matter (unless other evidence in respect thereof be
herein specifically prescribed) may be deemed to be conclusively
-30-
<PAGE>
proved and established by a certificate signed by a person believed by the
Rights Agent to be the Chairman of the Board, the President or any Vice
President and by the Treasurer or any Assistant Treasurer or the Secretary or
any Assistant Secretary of the Company and delivered to the Rights Agent; and
such certificate will be full authorization to the Rights Agent for any action
taken or suffered in good faith by it under the provisions of this Agreement in
reliance upon such certificate.
(c) The Rights Agent will be liable hereunder only for its own
negligence, bad faith or willful misconduct.
(d) The Rights Agent will not be liable for or by reason of any of
the statements of fact or recitals contained in this Agreement or in the
certificates for securities purchasable upon exercise of Rights or the Rights
Certificates (except its counter-signature thereof) or be required to verify the
same, but all such statements and recitals are and will be deemed to have been
made by the Company only.
(e) The Rights Agent will not be under any responsibility in respect
of the validity of this Agreement or the execution and delivery hereof (except
the due authorization, execution and delivery hereof by the Rights Agent) or in
respect of the validity or execution of any certificate for securities
purchasable upon exercise of Rights or Rights Certificate (except its
counter-signature thereof); nor will it be responsible for any breach by the
Company of any covenant or condition contained in this Agreement or in any
Rights Certificate; nor will it be responsible for any change in the
exercisability of the Rights (including the Rights becoming void pursuant to
Section 3.1(b) hereof) or any adjustment required under the provisions of
Section 2.4, 3.1 or 3.2 hereof or responsible for the manner, method or amount
of any such
-31-
<PAGE>
adjustment or the ascertaining of the existence of facts that would require any
such adjustment (except with respect to the exercise of Rights after receipt of
the certificate contemplated by Section 2.4 describing any such adjustment); nor
will it by any act hereunder be deemed to make any representation or warranty as
to the authorization or reservation of any securities purchasable upon exercise
of Rights or any Rights or as to whether any securities purchasable upon
exercise of Rights will, when issued, be duly and validly authorized, executed,
issued and delivered and fully paid and nonassessable.
(f) The Company agrees that it will perform, execute, acknowledge
and deliver or cause to be performed, executed, acknowledged and delivered all
such further and other acts, instruments and assurances as may reasonably be
required by the Rights Agent for the carrying out or performing by the Rights
Agent of the provisions of this Agreement.
(g) The Rights Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from any
person believed by the Rights Agent to be the Chairman of the Board, the
President or any Vice President or the Secretary or any Assistant Secretary or
the Treasurer or any Assistant Treasurer of the Company, and to apply to such
persons for advice or instructions in connection with its duties, and it shall
not be liable for any action taken or suffered by it in good faith in accordance
with instructions of any such person.
(h) The Rights Agent and any shareholder, director, officer or
employee of the Rights Agent may buy, sell or deal in Common Stock, Rights or
other securities of the Company or become pecuniarily interested in any
transaction in which the Company may be interested, or contract with or lend
money to the Company or otherwise act as fully and freely as though it
-32-
<PAGE>
were not Rights Agent under this Agreement. Nothing herein shall preclude the
Rights Agent from acting in any other capacity for the Company or for any other
legal entity.
(i) The Rights Agent may execute and exercise any of the rights or
powers hereby vested in it or perform any duty hereunder either itself or by or
through its attorneys or agents, and the Rights Agent will not be answerable or
accountable for any act, default, neglect or misconduct of any such attorneys or
agents or for any loss to the Company resulting from any such act, default,
neglect or misconduct, provided reasonable care was exercised in the selection
and continued employment thereof.
4.4 Change of Rights Agent.
----------------------
The Rights Agent may resign and be discharged from its duties under
this Agreement upon 90 days notice (or such lesser notice as is acceptable to
the Company) in writing mailed to the Company and to each transfer agent of
Common Stock by registered or certified mail, and to the holders of the Rights
in accordance with Section 5.9. The Company may remove the Rights Agent upon 30
days notice in writing, mailed to the Rights Agent and to each transfer agent of
the Common Stock by registered or certified mail, and to the holders of the
Rights in accordance with Section 5.9. If the Rights Agent should resign or be
removed or otherwise become incapable of acting, the Company will appoint a
successor to the Rights Agent. If the Company fails to make such appointment
within a period of 30 days after such removal or after it has been notified in
writing of such resignation or incapacity by the resigning or incapacitated
Rights Agent or by the holder of any Rights (which holder shall, with such
notice, submit such holder's Rights Certificate for inspection by the Company),
then the holder of any Rights may
-33-
<PAGE>
apply to any court of competent jurisdiction for the appointment of a new Rights
Agent. Any successor Rights Agent, whether appointed by the Company or by such a
court, shall be a corporation organized and doing business under the laws of the
United States or any state of the United States, in good standing, which is
authorized under such laws to exercise the powers of the Rights Agent
contemplated by this Agreement and is subject to supervision or examination by
federal or state authority and which has at the time of its appointment as
Rights Agent a combined capital and surplus of at least $50,000,000; provided,
however, that the Company is aware that as of the date of this Agreement
American Stock Transfer & Trust Company does not have a combined capital and
surplus of $50,000,000. After appointment, the successor Rights Agent will be
vested with the same powers, rights, duties and responsibilities as if it had
been originally named as Rights Agent without further act or deed; but the
predecessor Rights Agent shall deliver and transfer to the successor Rights
Agent any property at the time held by it hereunder, and execute and deliver any
further assurance, conveyance, act or deed necessary for the purpose. Not later
than the effective date of any such appointment, the Company will file notice
thereof in writing with the predecessor Rights Agent and each transfer agent of
the Common Stock, and mail a notice thereof in writing to the holders of the
Rights. Failure to give any notice provided for in this Section 4.4, however, or
any defect therein, shall not affect the legality or validity of the resignation
or removal of the Rights Agent or the appointment of the successor Rights Agent,
as the case may be.
-34-
<PAGE>
ARTICLE V
MISCELLANEOUS
5.1 Redemption.
----------
(a) The Board of Directors of the Company may, at its option, at any
time until 10 days after the Flip-in Date, elect to redeem all (but not less
than all) the then outstanding Rights at the Redemption Price and the Company,
at its option, may pay the Redemption Price either in cash or shares of Common
Stock or other securities of the Company deemed by the Board of Directors, in
the exercise of its sole discretion, to be at least equivalent in value to the
Redemption Price ; provided, however, that if the Board of Directors of the
Company authorizes redemption of the Rights in either of the circumstances set
forth in clauses (i) or (ii) below, then there must be Disinterested Directors
then in office and such authorization shall require the concurrence of a
majority of such Disinterested Directors: (i) such authorization occurs on or
after the time a Person becomes an Acquiring Person, or (ii) such authorization
occurs on or after the date of a change (resulting from a proxy or consent
solicitation) in a majority of the directors in office at the commencement of
such solicitation if any Person who is a participant in such solicitation has
stated (or if, upon the commencement of such solicitation, a majority of the
Board of Directors of the Company has determined in good faith) that such person
(or any of its Affiliates or Associates) intends to take, or may consider
taking, any action which would result in such Person or any Affiliate or
Associate of such Person becoming an Acquiring Person or causing a Flip-over
Transaction or Event. Notwithstanding anything contained in this
-35-
<PAGE>
Agreement to the contrary, the Rights shall not become exercisable until such
time as the Company's right of redemption pursuant to this Section 5.1 shall
expire.
(b) Immediately upon the action of the Board of Directors of the
Company electing to redeem the Rights (or, if the resolution of the Board of
Directors electing to redeem the Rights states that the redemption will not be
effective until the occurrence of a specified future time or event, upon the
occurrence of such future time or event), without any further action and without
any notice, the right to exercise the Rights will terminate and each Right will
thereafter represent only the right to receive the Redemption Price in cash or
securities, as determined by the Board of Directors. Promptly after the Rights
are redeemed, the Company shall give notice of such redemption to the Rights
Agent and the holders of the then outstanding Rights by mailing such notice in
accordance with Section 5.9.
5.2 Expiration.
----------
The Rights and this Agreement shall expire at the Expiration Time
and no Person shall have any rights pursuant to this Agreement or any Right
after the Expiration Time, except, if the Rights are exchanged or redeemed, as
provided in Section 3.1 or 5.1 hereof, respectively.
5.3 Issuance of New Rights Certificates.
-----------------------------------
Notwithstanding any of the provisions of this Agreement or of the
Rights to the contrary, the Company may, at its option, issue new Rights
Certificates evidencing Rights in such form as may be approved by its Board of
Directors to reflect any adjustment or change in the number or kind or class of
shares of stock purchasable upon exercise of Rights made in accordance with the
provisions of this Agreement. In addition, in connection with the issuance or
-36-
<PAGE>
sale of shares of Common Stock by the Company following the Separation Time and
prior to the Expiration Time pursuant to the terms of securities convertible or
redeemable into shares of Common Stock or to options, in each case issued or
granted prior to, and outstanding at, the Separation Time, the Company shall
issue to the holders of such shares of Common Stock, Rights Certificates
representing the appropriate number of Rights in connection with the issuance or
sale of such shares of Common Stock; provided, however, in each case, (i) no
such Rights Certificate shall be issued, if, and to the extent that, the Company
shall be advised by counsel that such issuance would create a significant risk
of material adverse tax consequences to the Company or to the Person to whom
such Rights Certificates would be issued, (ii) no such Rights Certificates shall
be issued if, and to the extent that, appropriate adjustment shall have
otherwise been made in lieu of the issuance thereof, and (iii) the Company shall
have no obligation to distribute Rights Certificates to any Acquiring Person or
Affiliate or Associate of an Acquiring Person or any transferee of any of the
foregoing.
5.4 Supplements and Amendments.
--------------------------
Prior to the Separation Date and subject to the penultimate sentence
of this Section 5.4, the Company may, and the Rights Agent shall if the Company
so directs, supplement or amend any provision of this Agreement without the
approval of any holders of Rights. From and after the Separation Date, and
subject to the penultimate sentence of this Section 5.4, the Company may, and
the Rights Agent shall if the Company so directs, supplement or amend this
Agreement without the approval of any holders of Rights in order (i) to cure any
ambiguity, (ii) to correct or supplement any provision contained herein which
may be
-37-
<PAGE>
defective or inconsistent with any other provisions herein, (iii) to change or
supplement the provisions hereunder in any manner which the Company may deem
necessary or desirable and which shall not adversely affect the interests of the
holders of Rights (other than an Acquiring Person or an Affiliate or Associate
of an Acquiring Person), (iv) to suspend the effectiveness of Section 3.1(b)
hereof (which suspension, following the first occurrence of an event set forth
in clauses (i) and (ii) of the proviso to Section 5.1(a) hereof, shall be
effective only if there are Disinterested Directors and shall require the
concurrence of a majority of such Disinterested Directors), or (v) to shorten or
lengthen any time period hereunder (which lengthening or shortening, following
the first occurrence of an event set forth in clauses (i) and (ii) of the
proviso of Section 5.1(a) hereof, shall be effective only if there are
Disinterested Directors and shall require the concurrence of a majority of such
Disinterested Directors); provided, this Agreement may not be supplemented or
amended to lengthen, pursuant to clause (v) of this sentence, (A) a time period
relating to when the Rights may be redeemed at such time as the Rights are not
then redeemable or (B) any other time period unless such lengthening is for the
purpose of protecting, enhancing or clarifying the rights of, and/or the
benefits to, the holders of Rights. Upon the delivery of a certificate from an
appropriate officer of the Company which states that the proposed supplement or
amendment is in compliance with the terms of this Section 5.4, the Rights Agent
shall execute such supplement or amendment. Notwithstanding anything contained
in this Agreement to the contrary, no supplement or amendment shall be made
after the Separation Date which (i) changes the Redemption Price, the Exercise
Price or the number of one one-hundredths of a share of Preferred Stock for
which a Right is exercisable or (ii) shortens the
-38-
<PAGE>
Expiration Time. Prior to the Separation Date, the interests of the holders of
Rights shall be deemed coincident with the interests of the holders of Common
Stock.
5.5 Fractional Shares.
-----------------
If the Company elects not to issue certificates representing
fractional shares upon exercise or redemption of Rights, the Company shall, in
lieu thereof, in the sole discretion of the Board of Directors, either (a)
evidence such fractional shares by depositary receipts issued pursuant to an
appropriate agreement between the Company and a depositary selected by it,
providing that each holder of a depositary receipt shall have all of the rights,
privileges and preferences to which such holder would be entitled as a
beneficial owner of such fractional share, or (b) pay to the registered holder
of such Rights the appropriate fraction of the Market Price per share in cash.
5.6 Rights of Action.
----------------
Subject to the terms of this Agreement (including Sections 3.1(b)
and 5.14), rights of action in respect of this Agreement, other than rights of
action vested solely in the Rights Agent, are vested in the respective holders
of the Rights; and any holder of any Rights, without the consent of the Rights
Agent or of the holder of any other Rights, may, on such holder's own behalf and
for such holder's own benefit and the benefit of other holders of Rights,
enforce, and may institute and maintain any suit, action or proceeding against
the Company to enforce, or otherwise act in respect of, such holder's right to
exercise such holder's Rights in the manner provided in such holder's Rights
Certificate and in this Agreement. Without limiting the foregoing or any
remedies available to the holders of Rights, it is specifically acknowledged
that
-39-
<PAGE>
the holders of Rights would not have an adequate remedy at law for any breach of
this Agreement and will be entitled to specific performance of the obligations
under, and injunctive relief against actual or threatened violations of, the
obligations of any Person subject to this Agreement.
5.7 Holder of Rights Not Deemed a Shareholder.
-----------------------------------------
No holder, as such, of any Rights shall be entitled to vote, receive
dividends or be deemed for any purpose the holder of shares or any other
securities which may at any time be issuable on the exercise of such Rights, nor
shall anything contained herein or in any Rights Certificate be construed to
confer upon the holder of any Rights, as such, any of the rights of a
shareholder of the Company or any right to vote for the election of directors or
upon any matter submitted to shareholders at any meeting thereof, or to give or
withhold consent to any corporate action, or to receive notice of meetings or
other actions affecting shareholders (except as provided in Section 5.8 hereof),
or to receive dividends or subscription rights, or otherwise, until such Rights
shall have been exercised or exchanged in accordance with the provisions hereof.
5.8 Notice of Proposed Actions.
---------------------------
In case the Company shall propose after the Separation Time and
prior to the Expiration Time (i) to effect or permit a Flip-over Transaction or
Event or (ii) to effect the liquidation, dissolution or winding up of the
Company, then, in each such case, the Company shall give to each holder of a
Right, in accordance with Section 5.9 hereof, a notice of such proposed action,
which shall specify the date on which such Flip-over Transaction or Event,
-40-
<PAGE>
liquidation, dissolution, or winding up is to take place, and such notice shall
be so given at least 20 Business Days prior to the date of the taking of such
proposed action.
5.9 Notices.
-------
Notices or demands authorized or required by this Agreement to be
given or made by the Rights Agent or by the holder of any Rights to or on the
Company shall be sufficiently given or made if delivered or sent by first-class
mail, postage prepaid, addressed (until another address is filed in writing with
the Rights Agent) as follows:
CollaGenex Pharmaceuticals, Inc.
301 South State Street
Newtown, Pennsylvania 18940
Attention: President
Any notice or demand authorized or required by this Agreement to be given or
made by the Company or by the holder of any Rights to or on the Rights Agent
shall be sufficiently given or made if delivered or sent by first-class mail,
postage prepaid, addressed (until another address is filed in writing with the
Company) as follows:
American Stock Transfer & Trust Company
40 Wall Street
New York, New York 10005
Attention: Corporate Trust Department
Any notice or demand authorized or required by this Agreement to be
given or made by the Company or the Rights Agent to or on the holder of any
Rights shall be sufficiently given or made if delivered or sent by first-class
mail, postage prepaid, addressed to such holder at the address of such holder as
it appears upon the registry books of the Rights Agent or, prior to the
-41-
<PAGE>
Separation Time, on the registry books of the transfer agent for the Common
Stock. Any notice which is mailed in the manner herein provided shall be deemed
given, whether or not the holder receives the notice.
5.10 Suspension of Exercisability.
----------------------------
To the extent that the Company determines in good faith that some
action will or need be taken pursuant to Section 3.1 or to comply with federal
or state securities laws, the Company may suspend the exercisability of the
Rights for a reasonable period in order to take such action or comply with such
laws. In the event of any such suspension, the Company shall issue as promptly
as practicable a public announcement stating that the exercisability or
exchangeability of the Rights has been temporarily suspended. Notice thereof
pursuant to Section 5.9 shall not be required.
Failure to give a notice pursuant to the provisions of this
Agreement shall not affect the validity of any action taken hereunder.
5.11 Costs of Enforcement.
--------------------
The Company agrees that if the Company or any other Person the
securities of which are purchasable upon exercise of Rights fails to fulfill any
of its obligations pursuant to this Agreement, then the Company or such Person
will reimburse the holder of any Rights for the costs and expenses (including
legal fees) incurred by such holder in actions to enforce such holder's rights
pursuant to any Rights or this Agreement.
-42-
<PAGE>
5.12 Successors.
----------
All the covenants and provisions of this Agreement by or for the
benefit of the Company or the Rights Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.
5.13 Benefits of this Agreement.
--------------------------
Nothing in this Agreement shall be construed to give to any Person
other than the Company, the Rights Agent and the holders of the Rights any legal
or equitable right, remedy or claim under this Agreement and this Agreement
shall be for the sole and exclusive benefit of the Company, the Rights Agent and
the holders of the Rights.
5.14 Determination and Actions by the Board of Directors, etc.
--------------------------------------------------------
The Board of Directors of the Company shall have the exclusive power
and authority to administer this Agreement and to exercise all rights and powers
specifically granted to the Board or to the Company, or as may be necessary or
advisable in the administration of this Agreement, including, without
limitation, the right and power to (i) interpret the provisions of this
Agreement and (ii) make all determinations deemed necessary or advisable for the
administration of this Agreement. All such actions, calculations,
interpretations and determinations (including, for purposes of clause (y) below,
all omissions with respect to the foregoing) which are done or made by the Board
in good faith, shall (x) be final, conclusive and binding on the Company, the
Rights Agent, the holders of the Rights and all other parties, and (y) not
subject the Board of Directors of the Company to any liability to the holders of
the Rights.
-43-
<PAGE>
5.15 Descriptive Headings.
--------------------
Descriptive headings appear herein for convenience only and shall
not control or affect the meaning or construction of any of the provisions
hereof.
5.16 Governing Law.
-------------
THIS AGREEMENT AND EACH RIGHT ISSUED HEREUNDER SHALL BE DEEMED TO BE
A CONTRACT MADE UNDER THE LAWS OF THE STATE OF DELAWARE AND FOR ALL PURPOSES
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF SUCH STATE
APPLICABLE TO CONTRACTS TO BE MADE AND PERFORMED ENTIRELY WITHIN SUCH STATE.
5.17 Counterparts.
------------
This Agreement may be executed in any number of counterparts and
each of such counterparts shall for all purposes be deemed to be an original,
and all such counterparts shall together constitute but one and the same
instrument.
5.18 Severability.
------------
If any term or provision hereof or the application thereof to any
circumstance shall, in any jurisdiction and to any extent, be invalid or
unenforceable, such term or provision shall be ineffective as to such
jurisdiction to the extent of such invalidity or unenforceability without
invalidating or rendering unenforceable the remaining terms and provisions
hereof or the application of such term or provision to circumstances other than
those as to which it is held invalid or unenforceable.
* * * * *
-44-
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the date first above written.
COLLAGENEX PHARMACEUTICALS, INC.
/s/ Nancy C. Broadbent
----------------------
Chief Financial Officer
AMERICAN STOCK TRANSFER &
TRUST COMPANY
/s/ Herbert J. Lemmer
---------------------
Vice President
-45-
<PAGE>
EXHIBIT A
---------
Form of Rights Certificate
Certificate No. W- Rights
----------
THE RIGHTS ARE SUBJECT TO REDEMPTION OR MANDATORY
EXCHANGE, AT THE OPTION OF THE COMPANY, ON THE
TERMS SET FORTH IN THE RIGHTS AGREEMENT. RIGHTS
BENEFICIALLY OWNED BY ACQUIRING PERSONS OR
AFFILIATES OR ASSOCIATES THEREOF (AS SUCH TERMS
ARE DEFINED IN THE RIGHTS AGREEMENT) OR TRANSFEREES
OF ANY OF THE FOREGOING WILL BE VOID.
Rights Certificate
COLLAGENEX PHARMACEUTICALS, INC.
This certifies that, or
----------------------------------------
registered assigns, is the registered holder of the number of Rights set forth
above, each of which entitles the registered holder thereof, subject to the
terms, provisions and conditions of the Shareholder Protection Rights Agreement,
dated as of September 15, 1997 (as amended from time to time, the "Rights
Agreement"), between CollaGenex Pharmaceuticals, Inc., a Delaware corporation
(the "Company"), and American Stock Transfer & Trust Company as Rights Agent
(the "Rights Agent," which term shall include any successor Rights Agent under
the Rights Agreement), to purchase from the Company at any time after the
Separation Time (as such term is defined in the Rights Agreement) and prior to
the close of business on September 26, 2007, one one-hundredth
<PAGE>
of a fully paid share of Participating Preferred Stock, no par value (the
"Preferred Stock"), of the Company (subject to adjustment as provided in the
Rights Agreement) at the Exercise Price referred to below, upon presentation and
surrender of this Rights Certificate with the Form of Election to Exercise duly
executed at the principal office of the Rights Agent in The City of New York.
The Exercise Price shall initially be $65.00 per Right and shall be subject to
adjustment in certain events as provided in the Rights Agreement.
In certain circumstances described in the Rights Agreement, the
Rights evidenced hereby may entitle the registered holder thereof to purchase
securities of an entity other than the Company or securities of the Company
other than Preferred Stock or assets of the Company, all as provided in the
Rights Agreement.
This Rights Certificate is subject to all of the terms, provisions
and conditions of the Rights Agreement, which terms, provisions and conditions
are hereby incorporated herein by reference and made a part hereof and to which
Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities hereunder of the
Rights Agent, the Company and the holders of the Rights Certificates. Copies of
the Rights Agreement are on file at the principal office of the Company and are
available without cost upon written request.
This Rights Certificate, with or without other Rights Certificates,
upon surrender at the office of the Rights Agent designated for such purpose,
may be exchanged for another Rights Certificate or Rights Certificates of like
tenor evidencing an aggregate number of Rights equal to the aggregate number of
Rights evidenced by the Rights Certificate or Rights Certificates surrendered.
If this Rights Certificate shall be exercised in part, the registered holder
-2-
<PAGE>
shall be entitled to receive, upon surrender hereof, another Rights Certificate
or Rights Certificates for the number of whole Rights not exercised.
Subject to the provisions of the Rights Agreement, each Right
evidenced by this Certificate may be (a) redeemed by the Company under certain
circumstances, at its option, at a redemption price of $0.01 per Right or (b)
exchanged by the Company under certain circumstances, at its option, for one
share of Common Stock or one one-hundredth of a share of Preferred Stock per
Right (or, in certain cases, other securities or assets of the Company), subject
in each case to adjustment in certain events as provided in the Rights
Agreement.
No holder of this Rights Certificate, as such, shall be entitled to
vote or receive dividends or be deemed for any purpose the holder of any
securities which may at any time be issuable on the exercise hereof, nor shall
anything contained in the Rights Agreement or herein be construed to confer upon
the holder hereof, as such, any of the rights of a shareholder of the Company or
any right to vote for the election of directors or upon any matter submitted to
shareholders at any meeting thereof, or to give or withhold consent to any
corporate action, or to receive notice of meetings or other actions affecting
shareholders (except as provided in the Rights Agreement), or to receive
dividends or subscription rights, or otherwise, until the Rights evidenced by
this Rights Certificate shall have been exercised or exchanged as provided in
the Rights Agreement.
This Rights Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Rights Agent.
-3-
<PAGE>
WITNESS the facsimile signature of the proper officers of the
Company and its corporate seal.
Date:
---------------------
ATTEST: COLLAGENEX PHARMACEUTICALS, INC.
- -------------------------- By:
Secretary ------------------------------
Name:
Title:
Countersigned:
- ---------------------------
By:
-----------------------
Authorized Signature
-4-
<PAGE>
Form of Reverse Side of Rights Certificate
FORM OF ASSIGNMENT
------------------
(To be executed by the registered holder if such
holder desires to transfer this Rights Certificate.)
FOR VALUE RECEIVED hereby sells, assigns and
--------------------
transfers unto (Please print name and
------------------------------------------
address of transferee) this Rights Certificate, together with all right, title
and interest therein, and does hereby irrevocably constitute and appoint
Attorney, to transfer the within Rights Certificate on the
- -------------------
books of the within-named Company, with full power of substitution.
Dated:
--------------------
Signature Guaranteed:
--------------------------------------
Signature
(Signature must correspond to name as
written upon the face of this Rights
Certificate in every particular, without
alteration or enlargement or any change
whatsoever)
Signatures must be guaranteed by an eligible guarantor institution
(banks, stockbrokers, savings and loan associations and credit unions with
membership in an approved signature guarantee Medallion program), pursuant to
SEC Rule 17Ad-15.
-5-
<PAGE>
- --------------------------------------------------------------------------------
(To be completed if true)
The undersigned hereby represents, for the benefit of all holders of Rights and
shares of Common Stock, that the Rights evidenced by this Rights Certificate are
not, and, to the knowledge of the undersigned, have never been, Beneficially
Owned by an Acquiring Person or an Affiliate or Associate thereof (as defined in
the Rights Agreement).
--------------------------------------
Signature
- --------------------------------------------------------------------------------
NOTICE
In the event the certification set forth above is not completed in
connection with a purported assignment, the Company will deem the Beneficial
Owner of the Rights evidenced by the enclosed Rights Certificate to be an
Acquiring Person or an Affiliate or Associate thereof (as defined in the Rights
Agreement) or a transferee of any of the foregoing and accordingly will deem the
Rights evidenced by such Rights Certificate to be void and not transferable or
exercisable.
-6-
<PAGE>
To be attached to each Rights Certificate
FORM OF ELECTION TO EXERCISE
----------------------------
(To be executed if holder desires to
exercise the Rights Certificate.)
TO: COLLAGENEX PHARMACEUTICALS, INC.
The undersigned hereby irrevocably elects to exercise
whole Rights represented by the attached Rights
- -----------------------
Certificate to purchase the shares of Participating Preferred Stock issuable
upon the exercise of such Rights and requests that certificates for such shares
be issued in the name of:
---------------------------------
(Name)
---------------------------------
(Address)
---------------------------------
---------------------------------
---------------------------------
(Social Security or Other Taxpayer ID)
-7-
<PAGE>
If such number of Rights shall not be all the Rights evidenced by this Rights
Certificate, a new Rights Certificate for the balance of such Rights shall be
registered in the name of and delivered to:
---------------------------------
(Name)
---------------------------------
(Address)
---------------------------------
---------------------------------
---------------------------------
(Social Security or Other Taxpayer ID)
Dated:
---------------------, -----
Signature Guaranteed:
--------------------------------------
Signature
(Signature must correspond to name as
written upon the face of the attached
Rights Certificate in every particular,
without alteration or enlargement or any
change whatsoever)
Signatures must be guaranteed by an eligible guarantor institution
(banks, stockbrokers, savings and loan associations and credit unions with
membership in an approved signature guarantee Medallion program), pursuant to
SEC Rule 17Ad-15.
-8-
<PAGE>
- --------------------------------------------------------------------------------
(To be completed if true)
The undersigned hereby represents, for the benefit of all holders of
Rights and shares of Common Stock, that the Rights evidenced by the attached
Rights Certificate are not, and, to the knowledge of the undersigned, have never
been, Beneficially Owned by an Acquiring Person or an Affiliate or Associate
thereof (as defined in the Rights Agreement).
-------------------------------
Signature
- --------------------------------------------------------------------------------
NOTICE
------
In the event the certification set forth above is not completed in
connection with a purported exercise, the Company will deem the Beneficial Owner
of the Rights evidenced by the attached Rights Certificate to be an Acquiring
Person or an Affiliate or Associate thereof (as defined in the Rights Agreement)
or a transferee of any of the foregoing and accordingly will deem the Rights
evidenced by such Rights Certificate to be void and not transferable or
exercisable.
-9-
<PAGE>
EXHIBIT B
---------
CERTIFICATE OF DESIGNATION
OF
SERIES A PARTICIPATING PREFERRED STOCK
OF
COLLAGENEX PHARMACEUTICALS, INC.
Pursuant to Section 151 of the Delaware General Corporation Law,
CollaGenex Pharmaceuticals, Inc., a corporation organized and existing under the
laws of the State of Delaware (the "Corporation"), DOES HEREBY CERTIFY THAT:
Pursuant to authority conferred upon the Board of Directors of the
Corporation by its Certificate of Incorporation and pursuant to the provisions
of Section 151 of the Delaware General Corporation Law, the Board of Directors
of the Corporation, at a duly called meeting thereof held on September 5, 1997,
adopted the following resolution:
RESOLVED, that there is hereby established a series of Preferred
Stock, no par value, of the Corporation, and the designation, number of
shares, and other relative rights, preferences and limitations of the
shares of such series are hereby fixed as follows:
(i) The distinctive serial designation of this series shall be
"Series A Participating Preferred Stock" (hereinafter called "this
Series"). Each share of this Series shall be identical in all respects
with the other shares of this Series except as to the dates from and
after which dividends thereon shall be cumulative.
(ii) The number of shares in this Series shall initially be
_______, which number may from time to time be increased or decreased
(but not below the number then outstanding) by the Board of Directors.
Shares of this Series purchased by the Corporation shall be canceled
and shall revert to authorized but unissued shares of Preferred Stock
undesignated as to series. Shares of this Series may be issued in
fractional shares, which fractional shares shall entitle the holder,
in proportion to such holder's fractional share, to all rights of a
holder of a whole share of this Series.
<PAGE>
(iii) The holders of full or fractional shares of this Series
shall be entitled to receive, when and as declared by the Board of
Directors, but only out of funds legally available therefor,
dividends, (A) on each date that dividends or other distributions
(other than dividends or distributions payable in Common Stock of the
Corporation) are payable on or in respect of Common Stock comprising
part of the Reference Package (as defined below), in an amount per
whole share of this Series equal to the aggregate amount of dividends
or other distributions (other than dividends or distributions payable
in Common Stock of the Corporation) that would be payable on such date
to a holder of the Reference Package and (B) on the last day of March,
June, September and December in each year, in an amount per whole
share of this Series equal to the excess (if any) of $___________1
over the aggregate dividends paid per whole share of this Series
during the three-month period ending on such last day. Each such
dividend shall be paid to the holders of record of shares of this
Series on the date, not exceeding sixty days preceding such dividend
or distribution payment date, fixed for the purpose by the Board of
Directors in advance of payment of each particular dividend or
distribution. Dividends on each full and each fractional share of this
Series shall be cumulative from the date such full or fractional share
is originally issued; provided that any such full or fractional share
originally issued after a dividend record date and on or prior to the
dividend payment date to which such record date relates shall not be
entitled to receive the dividend payable on such dividend payment date
or any amount in respect of the period from such original issuance to
such dividend payment date.
The term "Reference Package" shall initially mean 100 shares of
Common Stock, no par value ("Common Stock"), of the Corporation. In
the event the Corporation shall at any time after the close of
business on , _______, _______2 (A) declare or pay a dividend on any
Common Stock payable in Common Stock, (B) subdivide any Common Stock
or (C) combine any Common Stock into a smaller number of shares, then
and in each such case the Reference Package after such event shall be
the Common Stock that a holder of the Reference Package immediately
prior to such event would hold thereafter as a result thereof.
- ----------
1 Insert an amount equal to 1/4 of 1% of the Exercise Price divided by the
number of shares of Preferred Stock purchasable upon exercise of one Right.
2 For a certificate of designation relating to shares to be issued pursuant
to Section 2.3 of the Rights Agreement, insert the Separation Time. For a
certificate of designation relating to shares to be issued pursuant to
Section 3.1(d) of the Rights Agreement, insert the Flip-in Date
-2-
<PAGE>
Holders of shares of this Series shall not be entitled to any
dividends, whether payable in cash, property or stock, in excess of
full cumulative dividends, as herein provided on this Series.
So long as any shares of this Series are outstanding, no dividend
(other than a dividend in Common Stock or in any other stock ranking
junior to this Series as to dividends and upon liquidation) shall be
declared or paid or set aside for payment or other distribution
declared or made upon the Common Stock or upon any other stock ranking
junior to this Series as to dividends or upon liquidation, nor shall
any Common Stock nor any other stock of the Corporation ranking junior
to or on a parity with this Series as to dividends or upon liquidation
be redeemed, purchased or otherwise acquired for any consideration (or
any moneys be paid to or made available for a sinking fund for the
redemption of any shares of any such stock) by the Corporation (except
by conversion into or exchange for stock of the Corporation ranking
junior to this Series as to dividends and upon liquidation), unless,
in each case, the full cumulative dividends (including the dividend to
be due upon payment of such dividend, distribution, redemption,
purchase or other acquisition) on all outstanding shares of this
Series shall have been, or shall contemporaneously be, paid.
(iv) In the event of any merger, consolidation, reclassification
or other transaction in which the shares of Common Stock are exchanged
for or changed into other stock or securities, cash and/or any other
property, then in any such case the shares of this Series shall at the
same time be similarly exchanged or changed in an amount per whole
share equal to the aggregate amount of stock, securities, cash and/or
any other property (payable in kind), as the case may be, that a
holder of the Reference Package would be entitled to receive as a
result of such transaction.
(v) In the event of any liquidation, dissolution or winding up of
the affairs of the Corporation, whether voluntary or involuntary, the
holders of full and fractional shares of this Series shall be
entitled, before any distribution or payment is made on any date to
the holders of the Common Stock or any other stock of the Corporation
ranking junior to this Series upon liquidation, to be paid in full an
amount per whole share of this Series equal to the greater of (A)
$ 3 or (B) the aggregate amount distributed or to be
--------
distributed prior to such date in
- ----------
3 Insert an amount equal to 100 times the Exercise Price in effect as of the
Separation Time.
-3-
<PAGE>
connection with such liquidation, dissolution or winding up to a
holder of the Reference Package (such greater amount being hereinafter
referred to as the "Liquidation Preference"), together with accrued
dividends to such distribution or payment date, whether or not earned
or declared. If such payment shall have been made in full to all
holders of shares of this Series, the holders of shares of this Series
as such shall have no right or claim to any of the remaining assets of
the Corporation.
In the event the assets of the Corporation available for
distribution to the holders of shares of this Series upon any
liquidation, dissolution or winding up of the Corporation, whether
voluntary or involuntary, shall be insufficient to pay in full all
amounts to which such holders are entitled pursuant to the first
paragraph of this Section (v), no such distribution shall be made on
account of any shares of any other class or series of Preferred Stock
ranking on a parity with the shares of this Series upon such
liquidation, dissolution or winding up unless proportionate
distributive amounts shall be paid on account of the shares of this
Series, ratably in proportion to the full distributable amounts for
which holders of all such parity shares are respectively entitled upon
such liquidation, dissolution or winding up.
Upon the liquidation, dissolution or winding up of the
Corporation, the holders of shares of this Series then outstanding
shall be entitled to be paid out of assets of the Corporation
available for distribution to its shareholders all amounts to which
such holders are entitled pursuant to the first paragraph of this
Section (v) before any payment shall be made to the holders of
Common Stock or any other stock of the Corporation ranking junior
upon liquidation to this Series.
For the purposes of this Section (v), the consolidation or merger
of, or binding share exchange by, the Corporation with any other
corporation shall not be deemed to constitute a liquidation,
dissolution or winding up of the Corporation.
(vi) The shares of this Series shall not be redeemable.
(vii) In addition to any other vote or consent of shareholders
required by law or by the Certificate of Incorporation of the
Corporation, each whole share of this Series shall, on any matter,
vote as a class with any other capital stock comprising part of the
Reference Package and voting on such matter and shall have the number
of votes thereon that a holder of the Reference Package would have.
-4-
<PAGE>
IN WITNESS WHEREOF, the undersigned have signed and attested this
certificate on the _____ day of ___________________.
---------------------------------------
COLLAGENEX PHARMACEUTICALS ADOPTS
SHAREHOLDER RIGHTS PLAN
Newtown, PA -- September 16, 1997 -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:
CGPI) announced today that its Board of Directors has adopted a Shareholder
Rights Plan.
The Rights Plan provides, among other things, that upon the earlier of ten
days after a public announcement that a person has become a beneficial owner of
twenty percent or more of the voting power of all the Company's shares or ten
business days after a person announces an offer to acquire Company shares that
would give it twenty percent or more of the voting power, each right will become
exercisable to purchase Series A Participating Preferred Stock.
After the rights become exercisable, if a person or group acquires
beneficial ownership of shares representing twenty percent or more voting power,
or if the Company is acquired in a merger in which the Company survives, then
each right would entitle the holder (other than the acquiror) to purchase
Company common stock at fifty percent discount. Alternatively, if the Company is
acquired in a merger or other business combination, the rights permit holders to
purchase the common stock of the acquiror at a fifty percent discount.
The Rights Plan is designed to deter coercive or unfair takeover tactics
and to ensure that the Company's stockholders receive fair and equal treatment
in the event of an unsolicited attempt to acquire control of the Company. The
Rights Plan was not adopted in response to any effort to acquire the Company of
which the Board was aware.
Shareholders of record as of the close of business on September 26, 1997
and thereafter will receive the Rights, although no separate certificates will
be issued unless and until they detach and trade separately from the Common
Stock as described above. The new rights will expire on September 26, 2007
unless further extended, and will be subject to redemption by the Board of
Directors at $0.01 per right at any time prior to the first date upon which they
become exercisable. The rights themselves have no voting power, nor will they
entitle a holder to receive dividends.
CollaGenex Pharmaceuticals, Inc. is engaged in the development and
commercialization of innovative proprietary medical therapies for the treatment
of periodontal disease and other pathologies. The Company's lead drug,
Periostat(R), is pending FDA approval for the treatment of periodontal disease.
A new drug application for Periostat(R) was filed with the FDA in August 1996.
The Company's core technology involves inhibiting the activity of certain
enzymes that destroy the connective tissues of the body. In addition to
periodontal disease, the Company and its collaborators are researching and
developing other potential applications of the core technology, including cancer
metastasis, wound healing, osteoarthritis, osteoporosis, rheumatoid arthritis
and diabetic nephropathy.
<PAGE>
To receive additional information on CollaGenex Pharmaceuticals, Inc., via
fax, at no charge, dial 1-800-PRO-INFO and enter code CGPI, or visit the
Company's website at www.collagenex.com.
This news release contains forward-looking statements and therefore it
necessarily involves risks and uncertainties. Factors that could cause actual
events to differ from these forward-looking statements are set forth under the
caption "Risk Factors" in the Company's prospectus dated June 20, 1996, which is
part of its registration statement on file with the Securities and Exchange
Commission. There can be no assurance that the Company will receive regulatory
approval to market any product or, if such approval is received, that the
product will be commercially successful.
-2-
COLLAGENEX PHARMACEUTICALS CORPORATION
September , 1997
------
Dear Stockholder:
Your Board of Directors has adopted a Shareholder Protection Rights
Agreement (the "Plan"). The Plan is designed to protect the Company and you, its
stockholders, in the event of an unsolicited offer to acquire control of the
Company on terms that the Board of Directors determines to be not in the best
interests of the Company because the offer is abusive, coercive or otherwise
unfair. Such offers may include, for example, attempts to acquire control
without offering adequate consideration to all stockholders. The Plan is not
intended to prevent and will not prevent a takeover of the Company that the
Board determines to be in the best interests of the Company. Neither is the
Rights Plan intended to adversely affect the ability of a person to obtain
representation on the Company's Board by means of the proxy process. Under
Delaware law, the Board is charged with responding to a takeover offer in the
first instance, in a manner it determines to be in the best interests of the
Company. The Plan should assist the Board in carrying out this obligation.
As explained in greater detail in the attached Summary, the Rights will
become exercisable only if and when a situation that they were designed to
address does, in fact, arise. RIGHTS CERTIFICATES WILL NOT BE SENT TO YOU UNLESS
AND UNTIL THEY BECOME EXERCISABLE. The issuance of the Rights does not dilute
share value and does not affect earnings per share. The Rights are not presently
taxable to you or the Company under federal income tax law and they will not
change the manner in which you can presently trade shares of the Company's
common stock.
The Plan provides, among other things, that upon the earlier of ten
business days after a public announcement that a person has become a beneficial
owner of twenty percent or more of the voting power of all the Company's shares
or ten business days after a person announces an offer to acquire Company shares
that would give it twenty percent or more of the voting power, each Right will
become exercisable to purchase 1/100 of a share of the Company's Series A
Participating Preferred Stock.
After the Rights become exercisable, if the Company is acquired in a merger
in which the Company survives, or if a person or group acquires beneficial
ownership of shares representing twenty percent or more of the voting power of
the Company, then each Right, not previously exercised, would entitle the holder
(other than the acquiror) to purchase Company common stock at a fifty percent
discount to its market price. Alternatively, if the Company is acquired in a
merger or other business combination, the Rights permit holders to purchase the
common stock of the acquiror at a fifty percent discount to its market price.
The Rights will expire on September 26, 2007, unless further extended, and
will be subject to redemption by the Board of Directors at $0.01 per right at
any time prior to the first date on which they become exercisable.
<PAGE>
A copy of the Rights Agreement is available to any stockholder upon
request to CollaGenex Pharmaceuticals, Inc., Attn: Corporate Secretary, or by
telephone at (215) 579-7388.
Sincerely,
/s/ Brian M. Gallagher, Ph.D.
------------------------------------
President and Chief Executive Officer
-2-
<PAGE>
SUMMARY OF RIGHTS TO PURCHASE PREFERRED STOCK
The Board of Directors of CollaGenex Pharmaceuticals, Inc. (the "Company")
declared a distribution of one Right for each outstanding share of Common Stock
of the Company to stockholders of record at the close of business on September
26, 1997 and to each share of Common Stock that may be issued by the Company
prior to the "Separation Date" (or the earlier redemption or expiration of the
Rights) described below.
Operation of the Rights
-----------------------
Upon the occurrence of certain events described below, each Right would
entitle its holder to purchase from the Company one one-hundredth (1/100) of a
share of Series A Participating Preferred Stock, no par value (the "Preferred
Stock"), at a purchase price of $65.00 (the "Purchase Price"). Until the Rights
separate from the Common Stock, they cannot be exercised.
The Rights will separate from the Common Stock upon the earlier to occur of
(i) ten business days following a public announcement that a person or group of
affiliated or associated persons has acquired, or obtained the right to acquire,
beneficial ownership of shares of the Company's capital stock representing
twenty percent or more of the voting power of all outstanding shares of capital
stock of the Company or (ii) ten business days following the commencement of a
tender offer or exchange offer that would result in a person or group
beneficially owning outstanding shares of the Company's capital stock
representing twenty percent or more of the voting power of all outstanding
shares of capital stock of the Company (in each case, this person or group is
referenced as an "Acquiring Person"). The date upon which the Rights separate
from the Common Stock, and are thereby freely tradable, is called the
"Separation Date." The Separation Date can be delayed by an action of the Board
of Directors.
If, after the Separation Date, (i) the Company is the surviving
corporation in a merger with an Acquiring Person and its Common Stock is not
changed or exchanged, or (ii) an Acquiring Person becomes the beneficial owner
of shares of the Company's capital stock representing twenty percent or more of
the voting power of all outstanding shares of capital stock of the Company, each
holder of a Right (instead of having the right to receive Preferred Stock) will
thereafter have the right to receive, upon exercise, Common Stock having a value
equal to two times the exercise price of the Right. This is known as a "Flip-In"
Event. However, any Rights held by an Acquiring Person would not receive these
benefits.
In the event that, at any time following the Separation Date, (i) the
Company is acquired in certain merger or other business combination transactions
(other than a merger described above) in which it does not survive, or (ii)
fifty percent or more of the Company's assets or earning power is sold or
transferred, each holder of a Right (instead of having the right to purchase
Preferred Stock) will thereafter have the right to receive, upon exercise,
common stock of the acquiring company having a value equal to two times the
exercise price of the Right. This is known as a "Flip-Over" Event. For example,
assuming an exercise price of $65.00 per Right, each Right not owned by an
Acquiring Person (or by certain related parties) following a "Flip-In" or
"Flip-Over" Event would entitle its holder to purchase $130.00 worth of Common
Stock (or other
<PAGE>
consideration, as noted above) for $65.00. This would be Company Common
Stock if a "Flip-In" event occurred, and the Acquiring Person's common stock if
a "Flip-Over" event occurred.
Redemption of the Rights
------------------------
At any time until the Separation Date, the Board of Directors may
unilaterally redeem the Rights at a price of $0.01 per Right. This amount would
be paid to you and would mean that the Rights could no longer be exercised.
Under certain circumstances set forth in the Rights Agreement, the decision to
redeem would require the concurrence of a majority of the Disinterested
Directors (that is, a Board member who is unaffiliated with the Acquiring
Person). After the redemption period has expired, the Company's right of
redemption may be reinstated if an Acquiring Person reduces his beneficial
ownership to twenty percent or less of the voting power of the capital stock of
the Company in a transaction not involving the Company. Immediately upon the
action of the Board of Directors ordering redemption of the Rights with the
concurrence of a majority of the Disinterested Directors, if required, the
Rights will terminate and the only right of the holders of Rights will be to
receive the $0.01 redemption price.
The Board's Ability to Amend the Rights Plan
--------------------------------------------
Under the Rights Plan, the Board has broad powers to amend the Rights
Plan. Other than those provisions relating to the principal economic terms of
the Rights, any of the provisions of the Rights Agreement may be amended by the
Board prior to the Separation Date. After the Separation Date, amendments may
not adversely affect Right holders' interests. Under certain circumstances, an
amendment would require the concurrence of the Disinterested Directors.
Other Miscellaneous Provisions Under the Rights Plan
----------------------------------------------------
The Purchase Price payable, and the number of shares of Preferred Stock or
other securities or property issuable, upon exercise of the Rights are subject
to adjustment from time to time to prevent dilution (i) in the event of a stock
dividend on, or a subdivision, combination or reclassification of, the Preferred
Stock, (ii) if holders of the Preferred Stock are granted certain rights or
warrants to subscribe for Preferred Stock or convertible securities at less than
the current market price of the Preferred Stock, or (iii) upon the distribution
to holders of the Preferred Stock of evidences of indebtedness or assets
(excluding regular quarterly cash dividends) or of subscription rights or
warrants (other than those referred to above).
With certain exceptions, no adjustment in the Purchase Price will be
required until cumulative adjustments amount to at least one percent of the
Purchase Price.
Significance of the Rights Until Exercised
------------------------------------------
Until a Right is exercised, its holder has no claim as a stockholder of
the Company arising from the Right itself, including, without limitation, the
right to vote or to receive dividends. While the initial declaration and
distribution of the Rights will not be taxable to the stockholders or the
Company, stockholders may, depending upon the circumstances, recognize
-2-
<PAGE>
taxable income in the event that the Rights become exercisable for Common Stock
(or other consideration) of the Company or for common stock of an Acquiring
Person as set forth above.
Evidence of Ownership Of Rights
-------------------------------
Until the Separation Date, (i) the Rights will be evidenced by the Common
Stock certificates and will be transferred only with such Common Stock
certificates, (ii) new Common Stock certificates issued after September 26,
1997, will contain a notation incorporating the Rights Agreement by reference,
and (iii) the surrender for transfer of any certificates for Common Stock will
also constitute the transfer of the Rights associated with the Common Stock
represented by such certificate. TO REPEAT, NO SEPARATE RIGHTS CERTIFICATES WILL
BE DISTRIBUTED UNLESS AND UNTIL A SEPARATION DATE OCCURS. The Rights will expire
at the close of business on September 26, 2007, unless extended or earlier
redeemed by the Board as described below.
After the Separation Date (except as otherwise provided above), Rights
Certificates will be mailed to holders of record of the Common Stock as of the
close of business on a Separation Date and, thereafter, such separate Rights
Certificates alone will represent the Rights.
Other Information Available
---------------------------
This summary description of the Rights does not purport to be complete and
is qualified in its entirety by reference to the Rights Agreement that is
incorporated herein by reference. A copy of the Rights Agreement is available to
any stockholder upon request to CollaGenex Pharmaceuticals, Inc., Attn:
Corporate Secretary, or by telephone at (215) 579-7388.
